{
    "summary": {
      "total_tests": 857,
      "equivalent_results": 491,
      "different_results": 366,
      "high_significance_differences": 299,
      "medium_significance_differences": 59,
      "low_significance_differences": 8,
      "differences_by_focus": {
        "blast_thresholds": 12,
        "therapy_qualifiers": 1,
        "tp53_terminology": 6,
        "mds_blast_ranges": 18,
        "erythroid_handling": 8,
        "combination_scenarios": 2,
        "realistic_clinical_scenarios": 2,
        "age_dependent_differences": 10,
        "complex_cytogenetics": 2,
        "comutation_patterns": 4,
        "therapy_evolution": 2,
        "aml_vs_mds_borderline": 11,
        "disease_type_disagreement": 5,
        "comprehensive_germline_predisposition": 15,
        "vaf_threshold_testing": 9,
        "risk_stratification_boundaries": 3,
        "nuanced_dysplasia_patterns": 33,
        "clonal_evolution_patterns": 5,
        "cytogenetic_complexity_gradations": 200,
        "microenvironment_interactions": 8,
        "mrd_methodology_differences": 2,
        "prognostic_score_boundaries": 3,
        "lab_methodology_dependent": 5
      },
      "differences_by_category": {
        "major_clinical_impact": 89,
        "moderate_clinical_impact": 59,
        "significant_clinical_impact": 210,
        "minor_clinical_impact": 8
      }
    },
    "test_results": [
      {
        "test_id": "test_1_blast_thresholds",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877007",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_2_blast_thresholds",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877091",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_3_blast_thresholds",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877139",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_4_blast_thresholds",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "MDS with excess blasts",
          "who_category": "AML_GENETIC",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 85,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'npm1'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Favorable vs Unknown",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877236",
        "significance": "critical",
        "clinical_impact_score": 85,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'npm1'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Favorable vs Unknown",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_5_blast_thresholds",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877332",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_6_blast_thresholds",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 70,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'cebpa'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877398",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_7_blast_thresholds",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 65,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877458",
        "significance": "high",
        "clinical_impact_score": 65,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_8_blast_thresholds",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877495",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_9_blast_thresholds",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877551",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_10_blast_thresholds",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 70,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'cebpa'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877644",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_11_blast_thresholds",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 65,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877723",
        "significance": "high",
        "clinical_impact_score": 65,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_12_blast_thresholds",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877765",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_13_blast_thresholds",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877871",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_14_blast_thresholds",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 70,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'cebpa'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.877951",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_15_blast_thresholds",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 65,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878014",
        "significance": "high",
        "clinical_impact_score": 65,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": true
        }
      },
      {
        "test_id": "test_16_blast_thresholds",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878052",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_17_blast_thresholds",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML, NOS",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 55,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'cebpa'}",
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878110",
        "significance": "high",
        "clinical_impact_score": 55,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'cebpa'}",
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_18_blast_thresholds",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878150",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_19_blast_thresholds",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with BCR::ABL1 fusion",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878188",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_20_blast_thresholds",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878222",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_21_blast_thresholds",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML, NOS",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 55,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'cebpa'}",
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878276",
        "significance": "high",
        "clinical_impact_score": 55,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'cebpa'}",
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_22_blast_thresholds",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: bZIP",
          "bZIP with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878313",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "bZIP": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_23_blast_thresholds",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with BCR::ABL1 fusion",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with BCR::ABL1 fusion (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with BCR::ABL1 fusion",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878349",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_24_blast_thresholds",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "blast_thresholds",
        "timestamp": "2025-06-07T15:13:02.878381",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {},
          "expected_difference": false
        }
      },
      {
        "test_id": "test_25_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878424",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        }
      },
      {
        "test_id": "test_26_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878470",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        }
      },
      {
        "test_id": "test_27_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS, therapy related",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878530",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "expected_difference": true
        }
      },
      {
        "test_id": "test_28_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
          "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878575",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_29_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878622",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_30_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "icc_classification": "AML, NOS, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878671",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_31_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
          "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878715",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_32_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878761",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_33_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "icc_classification": "AML, NOS, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878806",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_34_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
          "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878848",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_35_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "Detected ICC therapy => therapy related: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878890",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_36_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected WHO therapy => previous cytotoxic therapy: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Any combination",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "icc_classification": "AML, NOS, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878935",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Any combination"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_37_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.878969",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_38_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879005",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_39_therapy_qualifiers",
        "input_data": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25.0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879041",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25.0,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "None"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_40_germline_qualifiers",
        "input_data": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "expected_difference": true
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Qualifier => in the setting of Diamond-Blackfan anemia",
          "Qualifiers appended => AML with mutated NPM1, in the setting of Diamond-Blackfan anemia (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1, in the setting of Diamond-Blackfan anemia",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "germline_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879087",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "expected_difference": true
        }
      },
      {
        "test_id": "test_41_germline_qualifiers",
        "input_data": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline BLM mutation"
          },
          "expected_difference": true
        },
        "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline BLM mutation",
          "Classification with qualifiers => AML with NPM1 mutation, associated with germline BLM mutation",
          "Final classification => AML with NPM1 mutation, associated with germline BLM mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, associated with germline BLM mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "germline_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879131",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline BLM mutation"
          },
          "expected_difference": true
        }
      },
      {
        "test_id": "test_42_germline_qualifiers",
        "input_data": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline CEBPA mutation",
          "Classification with qualifiers => AML with NPM1 mutation, associated with germline CEBPA mutation",
          "Final classification => AML with NPM1 mutation, associated with germline CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Qualifier => in the setting of germline CEBPA mutation",
          "Qualifiers appended => AML with mutated NPM1, in the setting of germline CEBPA mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, associated with germline CEBPA mutation",
          "icc_classification": "AML with mutated NPM1, in the setting of germline CEBPA mutation",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "germline_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879179",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_43_germline_qualifiers",
        "input_data": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => AML with NPM1 mutation, associated with germline DDX41 mutation",
          "Final classification => AML with NPM1 mutation, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => AML with mutated NPM1, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, associated with germline DDX41 mutation",
          "icc_classification": "AML with mutated NPM1, in the setting of germline DDX41 mutation",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "germline_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879224",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_44_germline_qualifiers",
        "input_data": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anaemia"
          },
          "expected_difference": false
        },
        "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia",
        "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Fanconi anaemia",
          "Classification with qualifiers => AML with NPM1 mutation, associated with Fanconi anaemia",
          "Final classification => AML with NPM1 mutation, associated with Fanconi anaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30.0",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Qualifier => in the setting of Fanconi anaemia",
          "Qualifiers appended => AML with mutated NPM1, in the setting of Fanconi anaemia (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, associated with Fanconi anaemia",
          "icc_classification": "AML with mutated NPM1, in the setting of Fanconi anaemia",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "germline_qualifiers",
        "timestamp": "2025-06-07T15:13:02.879270",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 30.0,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anaemia"
          },
          "expected_difference": false
        }
      },
      {
        "test_id": "test_45_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879313",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_46_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879361",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_47_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879403",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_48_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879448",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_49_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879490",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_50_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879524",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_51_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879564",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_52_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879641",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_53_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879695",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_54_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879759",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_55_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879810",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_56_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879860",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_57_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_LOH': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879902",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_58_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879948",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_59_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.879990",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_LOH": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_60_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880029",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_61_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880083",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_62_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880136",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_63_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880175",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_64_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880209",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_65_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880255",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_66_tp53_terminology",
        "input_data": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880294",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_67_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_TP53",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880348",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_68_tp53_terminology",
        "input_data": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880389",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 10,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_69_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_TP53",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880439",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_70_tp53_terminology",
        "input_data": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880492",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_71_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880538",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_72_tp53_terminology",
        "input_data": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880594",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_73_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880636",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_74_tp53_terminology",
        "input_data": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "tp53_terminology",
        "timestamp": "2025-06-07T15:13:02.880720",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_75_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, unclassifiable (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "number_of_dysplastic_lineages: None",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_NOS",
        "icc_disease_type": "MDS_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, unclassifiable",
          "icc_classification": "MDS, NOS",
          "who_category": "MDS_NOS",
          "icc_category": "MDS_NOS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880766",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_76_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "SF3B1 mutation detected => MDS with low blasts and SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "SF3B1 mutation detected => MDS with mutated SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with mutated SF3B1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_SF3B1",
        "icc_disease_type": "MDS_SF3B1",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts and SF3B1",
          "icc_classification": "MDS with mutated SF3B1",
          "who_category": "MDS_SF3B1",
          "icc_category": "MDS_SF3B1",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880808",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_77_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with low blasts and isolated 5q-",
        "icc_classification": "MDS with del(5q)",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "del(5q) detected => MDS with low blasts and isolated 5q-",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts and isolated 5q- (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "del(5q) detected => MDS with del(5q)",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with del(5q) (ICC 2022)"
        ],
        "who_disease_type": "MDS_5Q",
        "icc_disease_type": "MDS_5Q",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts and isolated 5q-",
          "icc_classification": "MDS with del(5q)",
          "who_category": "MDS_5Q",
          "icc_category": "MDS_5Q",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880850",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_78_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with low blasts",
        "icc_classification": "MDS, NOS with multilineage dysplasia",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "Multiple dysplastic lineages => MDS with low blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "number_of_dysplastic_lineages: 2",
          "Multilineage dysplasia => MDS, NOS with multilineage dysplasia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS with multilineage dysplasia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_DYSPLASIA",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts",
          "icc_classification": "MDS, NOS with multilineage dysplasia",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_DYSPLASIA",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880893",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_79_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: True",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, unclassifiable (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "number_of_dysplastic_lineages: None",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_NOS",
        "icc_disease_type": "MDS_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, unclassifiable",
          "icc_classification": "MDS, NOS",
          "who_category": "MDS_NOS",
          "icc_category": "MDS_NOS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880932",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_80_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS, hypoplastic",
        "icc_classification": "MDS, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "Hypoplasia detected => MDS, hypoplastic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, hypoplastic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "number_of_dysplastic_lineages: None",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, hypoplastic",
          "icc_classification": "MDS, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.880968",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 4,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_81_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881009",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_82_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881048",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_83_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881085",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_84_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881120",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_85_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: True",
          "5-9% blasts => MDS with increased blasts 1",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS with excess blasts",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881159",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_86_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881195",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_87_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881232",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_88_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881266",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_89_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881302",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_90_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881337",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_91_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: True",
          "5-9% blasts => MDS with increased blasts 1",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS with excess blasts",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881372",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_92_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881407",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_93_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881442",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_94_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881479",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_95_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881514",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_96_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881549",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_97_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: True",
          "5-9% blasts => MDS with increased blasts 1",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS with excess blasts",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881584",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_98_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881619",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_99_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881671",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_100_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881729",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_101_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881787",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_102_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881837",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_103_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881887",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_104_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881936",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 10,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_105_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.881988",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_106_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882044",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_107_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882100",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_108_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882170",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_109_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882231",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_110_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882288",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_111_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882341",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_112_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882399",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_113_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882454",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_114_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882513",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_115_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882601",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_116_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882699",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_117_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882766",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_118_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882862",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_119_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882933",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_120_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.882980",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_121_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.883019",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "fibrotic": true
        }
      },
      {
        "test_id": "test_122_mds_blast_ranges",
        "input_data": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mds_blast_ranges",
        "timestamp": "2025-06-07T15:13:02.883057",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "hypoplasia": true
        }
      },
      {
        "test_id": "test_123_erythroid_handling",
        "input_data": {
          "blasts_percentage": 15,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "AML_differentiation: M6a",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883111",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_124_erythroid_handling",
        "input_data": {
          "blasts_percentage": 20,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6a",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883161",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_125_erythroid_handling",
        "input_data": {
          "blasts_percentage": 25,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6a",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883208",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_126_erythroid_handling",
        "input_data": {
          "blasts_percentage": 30,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 30",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6a",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883257",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 30,
          "AML_differentiation": "M6a",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_127_erythroid_handling",
        "input_data": {
          "blasts_percentage": 15,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "AML_differentiation: M6b",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883304",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_128_erythroid_handling",
        "input_data": {
          "blasts_percentage": 20,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6b",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883351",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_129_erythroid_handling",
        "input_data": {
          "blasts_percentage": 25,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6b",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883396",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_130_erythroid_handling",
        "input_data": {
          "blasts_percentage": 30,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        },
        "who_classification": "Acute Erythroid leukaemia",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 30",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6b",
          "Erythroid subtype => Acute Erythroid leukaemia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute Erythroid leukaemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 30",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute Erythroid leukaemia",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "minor_clinical_impact",
          "significance": "low",
          "clinical_impact_score": 20,
          "clinical_consequences": [
            "Subtype classification differences within same disease category"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "erythroid_handling",
        "timestamp": "2025-06-07T15:13:02.883441",
        "significance": "low",
        "clinical_impact_score": 20,
        "clinical_consequences": [
          "Subtype classification differences within same disease category"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 30,
          "AML_differentiation": "M6b",
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "qualifiers": {}
        }
      },
      {
        "test_id": "test_131_combination_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA",
          "CEBPA found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS, therapy related",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "combination_scenarios",
        "timestamp": "2025-06-07T15:13:02.883509",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_132_combination_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "blasts_percentage": 20
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of Diamond-Blackfan anemia",
          "Qualifiers appended => AML with mutated TP53, in the setting of Diamond-Blackfan anemia (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML with mutated TP53, in the setting of Diamond-Blackfan anemia",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "combination_scenarios",
        "timestamp": "2025-06-07T15:13:02.883570",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "blasts_percentage": 20
        }
      },
      {
        "test_id": "test_133_combination_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "blasts_percentage": 12
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML with mutated TP53, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53, therapy related",
          "who_category": "MDS_TP53",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 50,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "combination_scenarios",
        "timestamp": "2025-06-07T15:13:02.883630",
        "significance": "high",
        "clinical_impact_score": 50,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_134_combination_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 25,
          "AML_differentiation": "M6a"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, SF3B1 => AML, myelodysplasia related",
          "AML_differentiation: M6a",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "combination_scenarios",
        "timestamp": "2025-06-07T15:13:02.883672",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 25,
          "AML_differentiation": "M6a"
        }
      },
      {
        "test_id": "test_135_edge_cases",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 0
        },
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 0",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 0, fibrotic: False",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, unclassifiable (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 0",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 0",
          "number_of_dysplastic_lineages: None",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_NOS",
        "icc_disease_type": "MDS_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, unclassifiable",
          "icc_classification": "MDS, NOS",
          "who_category": "MDS_NOS",
          "icc_category": "MDS_NOS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "edge_cases",
        "timestamp": "2025-06-07T15:13:02.883715",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 0
        }
      },
      {
        "test_id": "test_136_edge_cases",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 100
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 100",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 100",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "edge_cases",
        "timestamp": "2025-06-07T15:13:02.883752",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 100
        }
      },
      {
        "test_id": "test_137_edge_cases",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "RUNX1::RUNX1T1": true,
            "CBFB::MYH11": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 25
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, RUNX1::RUNX1T1, CBFB::MYH11",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "edge_cases",
        "timestamp": "2025-06-07T15:13:02.883786",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "RUNX1::RUNX1T1": true,
            "CBFB::MYH11": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 25
        }
      },
      {
        "test_id": "test_138_edge_cases",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true,
            "SF3B1": true,
            "SRSF2": true,
            "U2AF1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 8
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "edge_cases",
        "timestamp": "2025-06-07T15:13:02.883830",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true,
            "SF3B1": true,
            "SRSF2": true,
            "U2AF1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "blasts_percentage": 8
        }
      },
      {
        "test_id": "test_139_edge_cases",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true,
            "1_x_TP53_mutation_del_17p": true,
            "1_x_TP53_mutation_LOH": true,
            "1_x_TP53_mutation_50_percent_vaf": true,
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "qualifiers": {},
          "blasts_percentage": 15
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True, '1_x_TP53_mutation_del_17p': True, '1_x_TP53_mutation_LOH': True, '1_x_TP53_mutation_50_percent_vaf': True, '1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "edge_cases",
        "timestamp": "2025-06-07T15:13:02.883880",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true,
            "1_x_TP53_mutation_del_17p": true,
            "1_x_TP53_mutation_LOH": true,
            "1_x_TP53_mutation_50_percent_vaf": true,
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "qualifiers": {},
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_140_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "elderly_mds_with_tp53",
          "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
          "blasts_percentage": 12,
          "age": 75
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.883941",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "elderly_mds_with_tp53",
          "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
          "blasts_percentage": 12,
          "age": 75
        }
      },
      {
        "test_id": "test_141_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "young_adult_npm1_aml",
          "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
          "blasts_percentage": 85,
          "age": 28
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 85",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 85",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.883977",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "young_adult_npm1_aml",
          "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
          "blasts_percentage": 85,
          "age": 28
        }
      },
      {
        "test_id": "test_142_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_myeloid_malignancy": "Previous MDS"
          },
          "scenario_name": "aml_with_antecedent_mds",
          "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
          "blasts_percentage": 35
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884016",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_myeloid_malignancy": "Previous MDS"
          },
          "scenario_name": "aml_with_antecedent_mds",
          "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
          "blasts_percentage": 35
        }
      },
      {
        "test_id": "test_143_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "core_binding_factor_aml",
          "scenario_description": "Core-binding factor AML with good prognosis",
          "blasts_percentage": 45
        },
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1::RUNX1T1",
          "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with RUNX1::RUNX1T1 fusion",
          "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884055",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1::RUNX1T1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "core_binding_factor_aml",
          "scenario_description": "Core-binding factor AML with good prognosis",
          "blasts_percentage": 45
        }
      },
      {
        "test_id": "test_144_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "therapy_related_aml_tp53",
          "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
          "blasts_percentage": 65
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated TP53, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884105",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "therapy_related_aml_tp53",
          "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
          "blasts_percentage": 65
        }
      },
      {
        "test_id": "test_145_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_sf3b1_ring_sideroblasts",
          "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
          "blasts_percentage": 3,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 3, fibrotic: False",
          "SF3B1 mutation detected => MDS with low blasts and SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 3",
          "SF3B1 mutation detected => MDS with mutated SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with mutated SF3B1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_SF3B1",
        "icc_disease_type": "MDS_SF3B1",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts and SF3B1",
          "icc_classification": "MDS with mutated SF3B1",
          "who_category": "MDS_SF3B1",
          "icc_category": "MDS_SF3B1",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884146",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_sf3b1_ring_sideroblasts",
          "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
          "blasts_percentage": 3,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_146_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_mds",
          "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
          "blasts_percentage": 8,
          "hypoplasia": true,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884187",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_mds",
          "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
          "blasts_percentage": 8,
          "hypoplasia": true,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_147_realistic_clinical_scenarios",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_mds",
          "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
          "blasts_percentage": 15,
          "fibrotic": true
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "realistic_clinical_scenarios",
        "timestamp": "2025-06-07T15:13:02.884248",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_mds",
          "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
          "blasts_percentage": 15,
          "fibrotic": true
        }
      },
      {
        "test_id": "test_148_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "pediatric",
          "genetic_context": "cebpa_bzip"
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA, bZIP",
          "CEBPA with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA, bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884290",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "pediatric",
          "genetic_context": "cebpa_bzip"
        }
      },
      {
        "test_id": "test_149_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "pediatric",
          "genetic_context": "npm1_flt3"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884323",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "pediatric",
          "genetic_context": "npm1_flt3"
        }
      },
      {
        "test_id": "test_150_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "pediatric",
          "genetic_context": "runx1_germline"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884388",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "pediatric",
          "genetic_context": "runx1_germline"
        }
      },
      {
        "test_id": "test_151_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "pediatric",
          "genetic_context": "ddx41_germline"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
          "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884495",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "age": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "pediatric",
          "genetic_context": "ddx41_germline"
        }
      },
      {
        "test_id": "test_152_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "young_adult",
          "genetic_context": "cebpa_bzip"
        },
        "who_classification": "AML with CEBPA mutation",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA, bZIP",
          "CEBPA with blasts >=20 => AML with CEBPA mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA, bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with CEBPA mutation",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884536",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "young_adult",
          "genetic_context": "cebpa_bzip"
        }
      },
      {
        "test_id": "test_153_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "young_adult",
          "genetic_context": "npm1_flt3"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884568",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "young_adult",
          "genetic_context": "npm1_flt3"
        }
      },
      {
        "test_id": "test_154_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "young_adult",
          "genetic_context": "runx1_germline"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884626",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "young_adult",
          "genetic_context": "runx1_germline"
        }
      },
      {
        "test_id": "test_155_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "young_adult",
          "genetic_context": "ddx41_germline"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
        "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline DDX41 mutation",
          "icc_classification": "AML, NOS, in the setting of germline DDX41 mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884832",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "blasts_percentage": 20,
          "age": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "young_adult",
          "genetic_context": "ddx41_germline"
        }
      },
      {
        "test_id": "test_156_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "middle_aged",
          "genetic_context": "cebpa_bzip"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA, bZIP",
          "CEBPA found but blasts <20 => not AML by this route",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA, bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 70,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'cebpa'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884898",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "middle_aged",
          "genetic_context": "cebpa_bzip"
        }
      },
      {
        "test_id": "test_157_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "middle_aged",
          "genetic_context": "npm1_flt3"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.884935",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "middle_aged",
          "genetic_context": "npm1_flt3"
        }
      },
      {
        "test_id": "test_158_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "middle_aged",
          "genetic_context": "runx1_germline"
        },
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 35,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885003",
        "significance": "medium",
        "clinical_impact_score": 35,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "middle_aged",
          "genetic_context": "runx1_germline"
        }
      },
      {
        "test_id": "test_159_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "middle_aged",
          "genetic_context": "ddx41_germline"
        },
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
          "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885072",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "age": 55,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "middle_aged",
          "genetic_context": "ddx41_germline"
        }
      },
      {
        "test_id": "test_160_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "elderly",
          "genetic_context": "cebpa_bzip"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with in-frame bZIP mutated CEBPA",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA, bZIP",
          "CEBPA found but blasts <20 => not AML by this route",
          "bZIP found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA, bZIP",
          "bZIP => AML with in-frame bZIP mutated CEBPA",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with in-frame bZIP mutated CEBPA",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 70,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'cebpa'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885127",
        "significance": "high",
        "clinical_impact_score": 70,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'cebpa'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA": true,
            "bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "elderly",
          "genetic_context": "cebpa_bzip"
        }
      },
      {
        "test_id": "test_161_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "elderly",
          "genetic_context": "npm1_flt3"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885161",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "age_group": "elderly",
          "genetic_context": "npm1_flt3"
        }
      },
      {
        "test_id": "test_162_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "elderly",
          "genetic_context": "runx1_germline"
        },
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => MDS/AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "icc_classification": "MDS/AML, NOS, in the setting of germline RUNX1 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 35,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885222",
        "significance": "medium",
        "clinical_impact_score": 35,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "age_group": "elderly",
          "genetic_context": "runx1_germline"
        }
      },
      {
        "test_id": "test_163_age_dependent_differences",
        "input_data": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "elderly",
          "genetic_context": "ddx41_germline"
        },
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
          "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "age_dependent_differences",
        "timestamp": "2025-06-07T15:13:02.885289",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "age": 78,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "age_group": "elderly",
          "genetic_context": "ddx41_germline"
        }
      },
      {
        "test_id": "test_164_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 22,
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "MDS_related_mutation": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "complex_karyotype_tp53",
          "scenario_description": "Complex karyotype with TP53 mutation"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885348",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "MDS_related_mutation": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "complex_karyotype_tp53",
          "scenario_description": "Complex karyotype with TP53 mutation"
        }
      },
      {
        "test_id": "test_165_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 18,
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "del5q_syndrome_progression",
          "scenario_description": "del(5q) syndrome with blast progression"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885405",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "del5q_syndrome_progression",
          "scenario_description": "del(5q) syndrome with blast progression"
        }
      },
      {
        "test_id": "test_166_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 25,
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "MDS_related_mutation": {},
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "monosomy7_childhood",
          "scenario_description": "Monosomy 7 in young patient",
          "age": 8
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885447",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "MDS_related_mutation": {},
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "monosomy7_childhood",
          "scenario_description": "Monosomy 7 in young patient",
          "age": 8
        }
      },
      {
        "test_id": "test_167_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 45,
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "MDS_related_mutation": {
            "EVI1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "inv3_evi1_aml",
          "scenario_description": "inv(3) with EVI1 rearrangement"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): EVI1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885486",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 45,
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "MDS_related_mutation": {
            "EVI1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "inv3_evi1_aml",
          "scenario_description": "inv(3) with EVI1 rearrangement"
        }
      },
      {
        "test_id": "test_168_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 8,
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "MDS_related_mutation": {
            "RUNX1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "del7q_mds",
          "scenario_description": "del(7q) in MDS"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885529",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "MDS_related_mutation": {
            "RUNX1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "del7q_mds",
          "scenario_description": "del(7q) in MDS"
        }
      },
      {
        "test_id": "test_169_complex_cytogenetics",
        "input_data": {
          "blasts_percentage": 28,
          "MDS_related_cytogenetics": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "normal_karyotype_multiple_mutations",
          "scenario_description": "Normal karyotype with multiple mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): DNMT3A, TET2, ASXL1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "complex_cytogenetics",
        "timestamp": "2025-06-07T15:13:02.885566",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 28,
          "MDS_related_cytogenetics": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "Biallelic_TP53_mutation": {},
          "AML_defining_recurrent_genetic_abnormalities": {},
          "qualifiers": {},
          "scenario_name": "normal_karyotype_multiple_mutations",
          "scenario_description": "Normal karyotype with multiple mutations"
        }
      },
      {
        "test_id": "test_170_comutation_patterns",
        "input_data": {
          "blasts_percentage": 75,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "dnmt3a_npm1_flt3",
          "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885598",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 75,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "dnmt3a_npm1_flt3",
          "pattern_description": "DNMT3A + NPM1 + FLT3-ITD triple mutation"
        }
      },
      {
        "test_id": "test_171_comutation_patterns",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TET2": true,
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "tet2_sf3b1_mds",
          "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885636",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TET2": true,
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "tet2_sf3b1_mds",
          "pattern_description": "TET2 + SF3B1 in MDS with ring sideroblasts"
        }
      },
      {
        "test_id": "test_172_comutation_patterns",
        "input_data": {
          "blasts_percentage": 16,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "asxl1_runx1_poor_risk",
          "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885689",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 16,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "asxl1_runx1_poor_risk",
          "pattern_description": "ASXL1 + RUNX1 mutations - poor risk combination"
        }
      },
      {
        "test_id": "test_173_comutation_patterns",
        "input_data": {
          "blasts_percentage": 35,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "pattern_name": "tp53_complex_karyotype",
          "pattern_description": "TP53 mutation with complex karyotype"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885741",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 35,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "pattern_name": "tp53_complex_karyotype",
          "pattern_description": "TP53 mutation with complex karyotype"
        }
      },
      {
        "test_id": "test_174_comutation_patterns",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "srsf2_tet2_cmml_like",
          "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885798",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "srsf2_tet2_cmml_like",
          "pattern_description": "SRSF2 + TET2 mutations - CMML-like pattern"
        }
      },
      {
        "test_id": "test_175_comutation_patterns",
        "input_data": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "pattern_name": "u2af1_dnmt3a_secondary",
          "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
        },
        "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
        "icc_classification": "MDS with excess blasts, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
          "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic therapy",
          "Final classification => MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => MDS with excess blasts, therapy related",
          "Final classification => MDS with excess blasts, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1, previous cytotoxic therapy",
          "icc_classification": "MDS with excess blasts, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885850",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 9,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "pattern_name": "u2af1_dnmt3a_secondary",
          "pattern_description": "U2AF1 + DNMT3A in therapy-related MDS"
        }
      },
      {
        "test_id": "test_176_comutation_patterns",
        "input_data": {
          "blasts_percentage": 14,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "EZH2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "ezh2_asxl1_high_risk",
          "pattern_description": "EZH2 + ASXL1 high-risk combination"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 14, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comutation_patterns",
        "timestamp": "2025-06-07T15:13:02.885901",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 14,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "EZH2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "pattern_name": "ezh2_asxl1_high_risk",
          "pattern_description": "EZH2 + ASXL1 high-risk combination"
        }
      },
      {
        "test_id": "test_177_therapy_evolution",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "NRAS": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Previous MDS"
          },
          "scenario_name": "mds_to_aml_progression",
          "scenario_description": "MDS progression to AML with acquired mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1, NRAS => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_evolution",
        "timestamp": "2025-06-07T15:13:02.885940",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "NRAS": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Previous MDS"
          },
          "scenario_name": "mds_to_aml_progression",
          "scenario_description": "MDS progression to AML with acquired mutations"
        }
      },
      {
        "test_id": "test_178_therapy_evolution",
        "input_data": {
          "blasts_percentage": 45,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "post_chemo_aml_tp53",
          "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
        },
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
          "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_evolution",
        "timestamp": "2025-06-07T15:13:02.886018",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 45,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "post_chemo_aml_tp53",
          "scenario_description": "Therapy-related AML with TP53 after chemotherapy"
        }
      },
      {
        "test_id": "test_179_therapy_evolution",
        "input_data": {
          "blasts_percentage": 60,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "NPM1": true,
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "relapsed_aml_new_mutations",
          "scenario_description": "Relapsed AML with additional mutations"
        },
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with myelodysplasia related gene mutation, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): NPM1, TP53 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
          "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
          "icc_classification": "AML with myelodysplasia related gene mutation, therapy related",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "therapy_evolution",
        "timestamp": "2025-06-07T15:13:02.886089",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 60,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "NPM1": true,
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "relapsed_aml_new_mutations",
          "scenario_description": "Relapsed AML with additional mutations"
        }
      },
      {
        "test_id": "test_180_therapy_evolution",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "scenario_name": "post_radiation_mds",
          "scenario_description": "Radiation-induced MDS with del(5q)"
        },
        "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
          "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic therapy",
          "Final classification => MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, therapy related",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "therapy_evolution",
        "timestamp": "2025-06-07T15:13:02.886340",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "scenario_name": "post_radiation_mds",
          "scenario_description": "Radiation-induced MDS with del(5q)"
        }
      },
      {
        "test_id": "test_181_therapy_evolution",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "scenario_name": "immune_therapy_related",
          "scenario_description": "Post-immunotherapy myeloid neoplasm"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "therapy_evolution",
        "timestamp": "2025-06-07T15:13:02.886471",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "scenario_name": "immune_therapy_related",
          "scenario_description": "Post-immunotherapy myeloid neoplasm"
        }
      },
      {
        "test_id": "test_182_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_15_with_cebpa_bzip",
          "description": "15% blasts with CEBPA bZIP mutation - ICC may call AML, WHO may call MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886639",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_15_with_cebpa_bzip",
          "description": "15% blasts with CEBPA bZIP mutation - ICC may call AML, WHO may call MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_183_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_12_with_npm1",
          "description": "12% blasts with NPM1 mutation - borderline case",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_mutation",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_mutation",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886693",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_12_with_npm1",
          "description": "12% blasts with NPM1 mutation - borderline case",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_184_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_18_with_runx1_runx1t1",
          "description": "18% blasts with RUNX1-RUNX1T1 fusion",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1_RUNX1T1",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1_RUNX1T1",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886796",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_18_with_runx1_runx1t1",
          "description": "18% blasts with RUNX1-RUNX1T1 fusion",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_185_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_16_with_inv16",
          "description": "16% blasts with inv(16) - core binding factor",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 16,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CBFB_MYH11": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CBFB_MYH11",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CBFB_MYH11",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886878",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_16_with_inv16",
          "description": "16% blasts with inv(16) - core binding factor",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 16,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CBFB_MYH11": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_186_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_19_with_sf3b1_asxl1",
          "description": "19% blasts with SF3B1 and ASXL1 mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886942",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "blast_19_with_sf3b1_asxl1",
          "description": "19% blasts with SF3B1 and ASXL1 mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_187_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_21_with_tet2_dnmt3a",
          "description": "21% blasts with TET2 and DNMT3A mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 21,
          "MDS_related_mutation": {
            "TET2": true,
            "DNMT3A": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 21",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): TET2, DNMT3A => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 21",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.886982",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "blast_21_with_tet2_dnmt3a",
          "description": "21% blasts with TET2 and DNMT3A mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 21,
          "MDS_related_mutation": {
            "TET2": true,
            "DNMT3A": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_188_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_18_with_srsf2_u2af1",
          "description": "18% blasts with SRSF2 and U2AF1 mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887034",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "blast_18_with_srsf2_u2af1",
          "description": "18% blasts with SRSF2 and U2AF1 mutations",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_189_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "tr_blast_15_with_tp53",
          "description": "Therapy-related case with 15% blasts and TP53 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "therapy_qualifier": "Cytotoxic chemotherapy",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887088",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "tr_blast_15_with_tp53",
          "description": "Therapy-related case with 15% blasts and TP53 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "therapy_qualifier": "Cytotoxic chemotherapy",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_190_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "tr_blast_22_complex_karyotype",
          "description": "Therapy-related case with 22% blasts and complex karyotype",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 22,
          "complex_karyotype": true,
          "therapy_qualifier": "Ionising radiation",
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887125",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "tr_blast_22_complex_karyotype",
          "description": "Therapy-related case with 22% blasts and complex karyotype",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 22,
          "complex_karyotype": true,
          "therapy_qualifier": "Ionising radiation",
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_191_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "erythroid_blast_18_dysplastic",
          "description": "18% blasts with erythroid predominance and dysplasia",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_differentiation": "M6",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "AML_differentiation: M6",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887173",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "erythroid_blast_18_dysplastic",
          "description": "18% blasts with erythroid predominance and dysplasia",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_differentiation": "M6",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_192_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "erythroid_blast_25_with_sf3b1",
          "description": "25% blasts with erythroid features and SF3B1 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 25,
          "AML_differentiation": "M6",
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
          "AML_differentiation: M6",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887223",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "erythroid_blast_25_with_sf3b1",
          "description": "25% blasts with erythroid features and SF3B1 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 25,
          "AML_differentiation": "M6",
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_193_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_19_npm1_with_dysplasia",
          "description": "19% blasts with NPM1 mutation but significant dysplasia",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_mutation",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_mutation",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887279",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "blast_19_npm1_with_dysplasia",
          "description": "19% blasts with NPM1 mutation but significant dysplasia",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "dysplastic_lineages": 3,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_194_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_17_flt3_with_mds_changes",
          "description": "17% blasts with FLT3-ITD and MDS-related changes",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 17,
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "SRSF2": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 17",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: FLT3_ITD",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 17, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 17",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => FLT3_ITD",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887330",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "blast_17_flt3_with_mds_changes",
          "description": "17% blasts with FLT3-ITD and MDS-related changes",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 17,
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "SRSF2": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_195_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "blast_21_cebpa_with_complex_karyotype",
          "description": "21% blasts with CEBPA mutation and complex karyotype",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 21,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "complex_karyotype": true,
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 21",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 21",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887369",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "blast_21_cebpa_with_complex_karyotype",
          "description": "21% blasts with CEBPA mutation and complex karyotype",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 21,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "complex_karyotype": true,
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_196_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "previous_mds_blast_18",
          "description": "18% blasts in patient with previous MDS diagnosis",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "MDS_related_mutation": {
            "TET2": true,
            "SF3B1": true
          },
          "previous_mds_mpn": "Previous MDS",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887420",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "previous_mds_blast_18",
          "description": "18% blasts in patient with previous MDS diagnosis",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "MDS_related_mutation": {
            "TET2": true,
            "SF3B1": true
          },
          "previous_mds_mpn": "Previous MDS",
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_197_aml_vs_mds_borderline",
        "input_data": {
          "test_name": "previous_mds_blast_22_with_new_mutation",
          "description": "22% blasts with previous MDS and new AML-defining mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "MDS_related_mutation": {
            "TET2": true
          },
          "previous_mds_mpn": "Previous MDS",
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_mutation",
          "MDS-related mutation(s): TET2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_mutation",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "aml_vs_mds_borderline",
        "timestamp": "2025-06-07T15:13:02.887460",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "previous_mds_blast_22_with_new_mutation",
          "description": "22% blasts with previous MDS and new AML-defining mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "MDS_related_mutation": {
            "TET2": true
          },
          "previous_mds_mpn": "Previous MDS",
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_198_disease_type_disagreement",
        "input_data": {
          "test_name": "who_aml_icc_mds_blast_20_with_dysplasia",
          "description": "20% blasts with extensive dysplasia - WHO may favor AML, ICC may favor MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 20,
          "dysplastic_lineages": 3,
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true,
            "SRSF2": true
          },
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, TET2, SRSF2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887496",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "who_aml_icc_mds_blast_20_with_dysplasia",
          "description": "20% blasts with extensive dysplasia - WHO may favor AML, ICC may favor MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 20,
          "dysplastic_lineages": 3,
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true,
            "SRSF2": true
          },
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_199_disease_type_disagreement",
        "input_data": {
          "test_name": "blast_20_with_ring_sideroblasts",
          "description": "20% blasts with >15% ring sideroblasts and SF3B1 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 20,
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular",
          "ring_sideroblasts_percent": 25
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887531",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "test_name": "blast_20_with_ring_sideroblasts",
          "description": "20% blasts with >15% ring sideroblasts and SF3B1 mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 20,
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular",
          "ring_sideroblasts_percent": 25
        }
      },
      {
        "test_id": "test_200_disease_type_disagreement",
        "input_data": {
          "test_name": "who_mds_icc_aml_blast_15_cebpa",
          "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887581",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "who_mds_icc_aml_blast_15_cebpa",
          "description": "15% blasts with CEBPA bZIP - ICC may call AML, WHO may call MDS",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_201_disease_type_disagreement",
        "input_data": {
          "test_name": "blast_12_with_bcr_abl1",
          "description": "12% blasts with BCR::ABL1 fusion",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: BCR::ABL1",
          "BCR::ABL1 found but blasts <20 => not AML by this route",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => BCR::ABL1",
          "BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 65,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887637",
        "significance": "high",
        "clinical_impact_score": 65,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_12_with_bcr_abl1",
          "description": "12% blasts with BCR::ABL1 fusion",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {
            "BCR::ABL1": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_202_disease_type_disagreement",
        "input_data": {
          "test_name": "blast_18_with_kmt2a_rearrangement",
          "description": "18% blasts with KMT2A rearrangement",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {
            "KMT2A_rearranged": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: KMT2A_rearranged",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => KMT2A_rearranged",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887689",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "blast_18_with_kmt2a_rearrangement",
          "description": "18% blasts with KMT2A rearrangement",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {
            "KMT2A_rearranged": true
          },
          "dysplastic_lineages": 0,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_203_disease_type_disagreement",
        "input_data": {
          "test_name": "tr_blast_15_immune_intervention",
          "description": "15% blasts after immune intervention therapy",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "therapy_qualifier": "Immune interventions (ICC)",
          "MDS_related_mutation": {
            "TP53": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887747",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "test_name": "tr_blast_15_immune_intervention",
          "description": "15% blasts after immune intervention therapy",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 15,
          "therapy_qualifier": "Immune interventions (ICC)",
          "MDS_related_mutation": {
            "TP53": true
          },
          "dysplastic_lineages": 2,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_204_disease_type_disagreement",
        "input_data": {
          "test_name": "tr_blast_19_with_aml_mutation",
          "description": "19% blasts after chemotherapy with new AML-defining mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "therapy_qualifier": "Cytotoxic chemotherapy",
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_mutation",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 19, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 19",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_mutation",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "disease_type_disagreement",
        "timestamp": "2025-06-07T15:13:02.887798",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "test_name": "tr_blast_19_with_aml_mutation",
          "description": "19% blasts after chemotherapy with new AML-defining mutation",
          "expected_difference": true,
          "significance": "high",
          "blasts_percentage": 19,
          "therapy_qualifier": "Cytotoxic chemotherapy",
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_mutation": true
          },
          "dysplastic_lineages": 1,
          "bone_marrow_cellularity": "Hypercellular"
        }
      },
      {
        "test_id": "test_205_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 0,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline RUNX1 mutation",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of germline RUNX1 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 50,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.887870",
        "significance": "high",
        "clinical_impact_score": 50,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 0,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_206_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 1,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 8
        },
        "who_classification": "MDS with increased blasts 1, associated with germline RUNX1 mutation",
        "icc_classification": "MDS with excess blasts, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline RUNX1 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers: MDS with increased blasts 1, associated with germline RUNX1 mutation",
          "Final classification => MDS with increased blasts 1, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Classification with qualifiers => MDS with excess blasts, in the setting of germline RUNX1 mutation",
          "Final classification => MDS with excess blasts, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1, associated with germline RUNX1 mutation",
          "icc_classification": "MDS with excess blasts, in the setting of germline RUNX1 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.887932",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 1,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 8
        }
      },
      {
        "test_id": "test_207_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 2,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 65
        },
        "who_classification": "AML with NPM1 mutation, associated with germline RUNX1 mutation",
        "icc_classification": "AML with mutated NPM1, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => AML with NPM1 mutation, associated with germline RUNX1 mutation",
          "Final classification => AML with NPM1 mutation, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => AML with mutated NPM1, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, associated with germline RUNX1 mutation",
          "icc_classification": "AML with mutated NPM1, in the setting of germline RUNX1 mutation",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.887982",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 2,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 65
        }
      },
      {
        "test_id": "test_208_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 3,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 25
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
        "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline RUNX1 mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline RUNX1 mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline RUNX1 mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline RUNX1 mutation",
          "icc_classification": "AML, NOS, in the setting of germline RUNX1 mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888045",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "germline RUNX1 mutation"
          },
          "syndrome_name": "germline_runx1_adult",
          "syndrome_description": "Adult with germline RUNX1 mutation and acquired second hits",
          "combination_index": 3,
          "age": 45,
          "family_history": true,
          "blasts_percentage": 25
        }
      },
      {
        "test_id": "test_209_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 0,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 5
        },
        "who_classification": "MDS with increased blasts 1, associated with germline DDX41 mutation",
        "icc_classification": "MDS with excess blasts, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 1, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 1, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Classification with qualifiers => MDS with excess blasts, in the setting of germline DDX41 mutation",
          "Final classification => MDS with excess blasts, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1, associated with germline DDX41 mutation",
          "icc_classification": "MDS with excess blasts, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888106",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 0,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 5
        }
      },
      {
        "test_id": "test_210_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 1,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 12
        },
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888176",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 1,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_211_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 2,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
        "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 2, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 2, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Qualifiers appended => MDS/AML, NOS, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with germline DDX41 mutation",
          "icc_classification": "MDS/AML, NOS, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888243",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 2,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_212_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 3,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 9
        },
        "who_classification": "MDS with increased blasts 1, associated with germline DDX41 mutation",
        "icc_classification": "MDS with excess blasts, in the setting of germline DDX41 mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "Final classification => Not AML, consider MDS classification, associated with germline DDX41 mutation",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "Detected germline predisposition => associated with germline DDX41 mutation",
          "Classification with qualifiers: MDS with increased blasts 1, associated with germline DDX41 mutation",
          "Final classification => MDS with increased blasts 1, associated with germline DDX41 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "Qualifier => in the setting of germline DDX41 mutation",
          "Classification with qualifiers => MDS with excess blasts, in the setting of germline DDX41 mutation",
          "Final classification => MDS with excess blasts, in the setting of germline DDX41 mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1, associated with germline DDX41 mutation",
          "icc_classification": "MDS with excess blasts, in the setting of germline DDX41 mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888299",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline DDX41 mutation"
          },
          "syndrome_name": "germline_ddx41_elderly",
          "syndrome_description": "Elderly patient with germline DDX41 mutation",
          "combination_index": 3,
          "age": 72,
          "family_history": true,
          "blasts_percentage": 9
        }
      },
      {
        "test_id": "test_213_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 0,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 45
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
        "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline CEBPA mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline CEBPA mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline CEBPA mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888365",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 0,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 45
        }
      },
      {
        "test_id": "test_214_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 1,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 55
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
        "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: FLT3_ITD",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline CEBPA mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => FLT3_ITD",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline CEBPA mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline CEBPA mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888427",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 1,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 55
        }
      },
      {
        "test_id": "test_215_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 2,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 35,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
        "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with germline CEBPA mutation",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of germline CEBPA mutation",
          "Qualifiers appended => AML, NOS, in the setting of germline CEBPA mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with germline CEBPA mutation",
          "icc_classification": "AML, NOS, in the setting of germline CEBPA mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_GENETIC",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 30,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888486",
        "significance": "medium",
        "clinical_impact_score": 30,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "germline CEBPA mutation"
          },
          "syndrome_name": "germline_cebpa_young_adult",
          "syndrome_description": "Young adult with germline CEBPA mutation",
          "combination_index": 2,
          "age": 28,
          "family_history": true,
          "blasts_percentage": 35,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_216_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 0,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2, associated with GATA2 deficiency syndrome",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of GATA2 deficiency syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with GATA2 deficiency syndrome",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with GATA2 deficiency syndrome",
          "Final classification => Not AML, consider MDS classification, associated with GATA2 deficiency syndrome",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with GATA2 deficiency syndrome",
          "Classification with qualifiers: MDS with increased blasts 2, associated with GATA2 deficiency syndrome",
          "Final classification => MDS with increased blasts 2, associated with GATA2 deficiency syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Qualifier => in the setting of GATA2 deficiency syndrome",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, in the setting of GATA2 deficiency syndrome (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with GATA2 deficiency syndrome",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of GATA2 deficiency syndrome",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888560",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 0,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_217_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 1,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 25
        },
        "who_classification": "AML, myelodysplasia related, associated with GATA2 deficiency syndrome",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, in the setting of GATA2 deficiency syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with GATA2 deficiency syndrome",
          "Classification with qualifiers => AML, myelodysplasia related, associated with GATA2 deficiency syndrome",
          "Final classification => AML, myelodysplasia related, associated with GATA2 deficiency syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of GATA2 deficiency syndrome",
          "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, in the setting of GATA2 deficiency syndrome (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, associated with GATA2 deficiency syndrome",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, in the setting of GATA2 deficiency syndrome",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888622",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 1,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 25
        }
      },
      {
        "test_id": "test_218_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 2,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 35,
          "number_of_dysplastic_lineages": 3
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with GATA2 deficiency syndrome",
        "icc_classification": "AML, NOS, in the setting of GATA2 deficiency syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with GATA2 deficiency syndrome",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with GATA2 deficiency syndrome",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with GATA2 deficiency syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of GATA2 deficiency syndrome",
          "Qualifiers appended => AML, NOS, in the setting of GATA2 deficiency syndrome (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with GATA2 deficiency syndrome",
          "icc_classification": "AML, NOS, in the setting of GATA2 deficiency syndrome",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Germline implications differ",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Family screening recommendations differ",
            "Drug toxicity considerations differ"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888690",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Germline implications differ",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "GATA2 deficiency syndrome"
          },
          "syndrome_name": "germline_gata2_pediatric",
          "syndrome_description": "Pediatric patient with GATA2 deficiency syndrome",
          "combination_index": 2,
          "age": 14,
          "immunodeficiency": true,
          "monocytopenia": true,
          "blasts_percentage": 35,
          "number_of_dysplastic_lineages": 3
        }
      },
      {
        "test_id": "test_219_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 0,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 45
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
        "icc_classification": "AML with mutated TP53, therapy related, in the setting of Li-Fraumeni syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "Detected germline predisposition => associated with Li-Fraumeni syndrome",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy, associated with Li-Fraumeni syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "Qualifier => in the setting of Li-Fraumeni syndrome",
          "Qualifiers appended => AML with mutated TP53, therapy related, in the setting of Li-Fraumeni syndrome (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "icc_classification": "AML with mutated TP53, therapy related, in the setting of Li-Fraumeni syndrome",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888754",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 0,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 45
        }
      },
      {
        "test_id": "test_220_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 1,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 22
        },
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related, in the setting of Li-Fraumeni syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "Detected germline predisposition => associated with Li-Fraumeni syndrome",
          "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "Final classification => AML, myelodysplasia related, previous cytotoxic therapy, associated with Li-Fraumeni syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "Qualifier => in the setting of Li-Fraumeni syndrome",
          "Qualifiers appended => AML with myelodysplasia related cytogenetic abnormality, therapy related, in the setting of Li-Fraumeni syndrome (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality, therapy related, in the setting of Li-Fraumeni syndrome",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888821",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 1,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 22
        }
      },
      {
        "test_id": "test_221_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 2,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
        "icc_classification": "MDS/AML, NOS, therapy related, in the setting of Li-Fraumeni syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "Detected germline predisposition => associated with Li-Fraumeni syndrome",
          "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "Detected germline predisposition => associated with Li-Fraumeni syndrome",
          "Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "Final classification => MDS with increased blasts 2, previous cytotoxic therapy, associated with Li-Fraumeni syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "Qualifier => in the setting of Li-Fraumeni syndrome",
          "Qualifiers appended => MDS/AML, NOS, therapy related, in the setting of Li-Fraumeni syndrome (ICC 2022)"
        ],
        "who_disease_type": "AML_THERAPY_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, previous cytotoxic therapy, associated with Li-Fraumeni syndrome",
          "icc_classification": "MDS/AML, NOS, therapy related, in the setting of Li-Fraumeni syndrome",
          "who_category": "AML_THERAPY_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888881",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Li-Fraumeni syndrome",
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "syndrome_name": "germline_tp53_li_fraumeni",
          "syndrome_description": "Li-Fraumeni syndrome with hematologic manifestation",
          "combination_index": 2,
          "age": 35,
          "family_history": true,
          "cancer_history": "Previous breast cancer",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_222_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "EZH2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Weaver syndrome"
          },
          "syndrome_name": "germline_ezh2_weaver_syndrome",
          "syndrome_description": "Weaver syndrome with germline EZH2 mutation",
          "combination_index": 0,
          "age": 22,
          "developmental_abnormalities": true,
          "blasts_percentage": 12
        },
        "who_classification": "MDS with increased blasts 2, associated with Weaver syndrome",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of Weaver syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Weaver syndrome",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with Weaver syndrome",
          "Final classification => Not AML, consider MDS classification, associated with Weaver syndrome",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with Weaver syndrome",
          "Classification with qualifiers: MDS with increased blasts 2, associated with Weaver syndrome",
          "Final classification => MDS with increased blasts 2, associated with Weaver syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Qualifier => in the setting of Weaver syndrome",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, in the setting of Weaver syndrome (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with Weaver syndrome",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of Weaver syndrome",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.888951",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "EZH2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Weaver syndrome"
          },
          "syndrome_name": "germline_ezh2_weaver_syndrome",
          "syndrome_description": "Weaver syndrome with germline EZH2 mutation",
          "combination_index": 0,
          "age": 22,
          "developmental_abnormalities": true,
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_223_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Weaver syndrome"
          },
          "syndrome_name": "germline_ezh2_weaver_syndrome",
          "syndrome_description": "Weaver syndrome with germline EZH2 mutation",
          "combination_index": 1,
          "age": 22,
          "developmental_abnormalities": true,
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1, associated with Weaver syndrome",
        "icc_classification": "MDS with excess blasts, in the setting of Weaver syndrome",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Weaver syndrome",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with Weaver syndrome",
          "Final classification => Not AML, consider MDS classification, associated with Weaver syndrome",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "Detected germline predisposition => associated with Weaver syndrome",
          "Classification with qualifiers: MDS with increased blasts 1, associated with Weaver syndrome",
          "Final classification => MDS with increased blasts 1, associated with Weaver syndrome (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "Qualifier => in the setting of Weaver syndrome",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "Qualifier => in the setting of Weaver syndrome",
          "Classification with qualifiers => MDS with excess blasts, in the setting of Weaver syndrome",
          "Final classification => MDS with excess blasts, in the setting of Weaver syndrome (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1, associated with Weaver syndrome",
          "icc_classification": "MDS with excess blasts, in the setting of Weaver syndrome",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889008",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Weaver syndrome"
          },
          "syndrome_name": "germline_ezh2_weaver_syndrome",
          "syndrome_description": "Weaver syndrome with germline EZH2 mutation",
          "combination_index": 1,
          "age": 22,
          "developmental_abnormalities": true,
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_224_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 0,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2, associated with Fanconi anemia",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, in the setting of Fanconi anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with Fanconi anemia",
          "Final classification => Not AML, consider MDS classification, associated with Fanconi anemia",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers: MDS with increased blasts 2, associated with Fanconi anemia",
          "Final classification => MDS with increased blasts 2, associated with Fanconi anemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "Qualifier => in the setting of Fanconi anemia",
          "Qualifiers appended => MDS/AML with myelodysplasia related cytogenetic abnormality, in the setting of Fanconi anemia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with Fanconi anemia",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality, in the setting of Fanconi anemia",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889080",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 0,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_225_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 1,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 25,
          "number_of_dysplastic_lineages": 3
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with Fanconi anemia",
        "icc_classification": "AML, NOS, in the setting of Fanconi anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, associated with Fanconi anemia",
          "Final classification => Acute myeloid leukaemia, unknown differentiation, associated with Fanconi anemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of Fanconi anemia",
          "Qualifiers appended => AML, NOS, in the setting of Fanconi anemia (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation, associated with Fanconi anemia",
          "icc_classification": "AML, NOS, in the setting of Fanconi anemia",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Germline implications differ",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Family screening recommendations differ",
            "Drug toxicity considerations differ"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889146",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Germline implications differ",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 1,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 25,
          "number_of_dysplastic_lineages": 3
        }
      },
      {
        "test_id": "test_226_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 2,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 35
        },
        "who_classification": "AML, myelodysplasia related, associated with Fanconi anemia",
        "icc_classification": "AML with myelodysplasia related gene mutation, in the setting of Fanconi anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): TP53 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers => AML, myelodysplasia related, associated with Fanconi anemia",
          "Final classification => AML, myelodysplasia related, associated with Fanconi anemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of Fanconi anemia",
          "Qualifiers appended => AML with myelodysplasia related gene mutation, in the setting of Fanconi anemia (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, associated with Fanconi anemia",
          "icc_classification": "AML with myelodysplasia related gene mutation, in the setting of Fanconi anemia",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889202",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "syndrome_name": "fanconi_anemia_brca2",
          "syndrome_description": "Fanconi anemia with BRCA2 mutation",
          "combination_index": 2,
          "age": 18,
          "chromosome_fragility": true,
          "growth_retardation": true,
          "blasts_percentage": 35
        }
      },
      {
        "test_id": "test_227_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 0,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "erythroid_dysplasia": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS, in the setting of Diamond-Blackfan anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of Diamond-Blackfan anemia",
          "Qualifiers appended => MDS/AML, NOS, in the setting of Diamond-Blackfan anemia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS, in the setting of Diamond-Blackfan anemia",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889297",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 0,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "erythroid_dysplasia": true
        }
      },
      {
        "test_id": "test_228_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 1,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "AML_differentiation": "M6",
          "blasts_percentage": 28
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS, in the setting of Diamond-Blackfan anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "AML_differentiation: M6",
          "No valid AML_differentiation => unknown differentiation",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "Qualifier => in the setting of Diamond-Blackfan anemia",
          "Qualifiers appended => AML, NOS, in the setting of Diamond-Blackfan anemia (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS, in the setting of Diamond-Blackfan anemia",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 35,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Germline implications differ"
          ],
          "treatment_implications": [
            "Family screening recommendations differ",
            "Drug toxicity considerations differ"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889359",
        "significance": "medium",
        "clinical_impact_score": 35,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 1,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "AML_differentiation": "M6",
          "blasts_percentage": 28
        }
      },
      {
        "test_id": "test_229_comprehensive_germline_predisposition",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 2,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of Diamond-Blackfan anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Qualifier => in the setting of Diamond-Blackfan anemia",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, in the setting of Diamond-Blackfan anemia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, in the setting of Diamond-Blackfan anemia",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "comprehensive_germline_predisposition",
        "timestamp": "2025-06-07T15:13:02.889424",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Diamond-Blackfan anemia"
          },
          "syndrome_name": "diamond_blackfan_anemia",
          "syndrome_description": "Diamond-Blackfan anemia progression to MDS/AML",
          "combination_index": 2,
          "age": 25,
          "ribosomal_protein_defect": true,
          "anemia_history": true,
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_230_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_10_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_TP53",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889479",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_10_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_231_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_25_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "intermediate",
          "clonality": "unknown",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_25_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889528",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_25_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "intermediate",
          "clonality": "unknown",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_232_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889638",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_233_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_90_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "very_high",
          "clonality": "unknown",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_90_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889687",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_90_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_vaf_gradations",
          "scenario_description": "TP53 mutations at different VAF levels",
          "vaf_level": "very_high",
          "clonality": "unknown",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_234_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_15_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_15_percent_vaf",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_15_percent_vaf",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889737",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_15_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_235_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_35_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "intermediate",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_35_percent_vaf",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_35_percent_vaf",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889787",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_35_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "intermediate",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_236_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_60_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1_60_percent_vaf",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1_60_percent_vaf",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889835",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1_60_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_vaf_impact",
          "scenario_description": "NPM1 mutations at different VAF levels in borderline blast cases",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_237_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP_20_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "cebpa_vaf_bzip_interaction",
          "scenario_description": "CEBPA bZIP mutations at different VAF levels",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP_20_percent_vaf",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP_20_percent_vaf",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889882",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP_20_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "cebpa_vaf_bzip_interaction",
          "scenario_description": "CEBPA bZIP mutations at different VAF levels",
          "vaf_level": "low",
          "clonality": "unknown",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_238_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP_45_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "cebpa_vaf_bzip_interaction",
          "scenario_description": "CEBPA bZIP mutations at different VAF levels",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP_45_percent_vaf",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP_45_percent_vaf",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889930",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP_45_percent_vaf": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "cebpa_vaf_bzip_interaction",
          "scenario_description": "CEBPA bZIP mutations at different VAF levels",
          "vaf_level": "high",
          "clonality": "unknown",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_239_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "subclonal",
          "blasts_percentage": 20
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): DNMT3A, TET2_subclonal_15_percent, TET2_clonal_45_percent => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.889972",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "subclonal",
          "blasts_percentage": 20
        }
      },
      {
        "test_id": "test_240_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "clonal",
          "blasts_percentage": 20
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): DNMT3A, TET2_subclonal_15_percent, TET2_clonal_45_percent => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.890013",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "clonal",
          "blasts_percentage": 20
        }
      },
      {
        "test_id": "test_241_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD_subclonal_25_percent": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "subclonal",
          "blasts_percentage": 20
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: FLT3_ITD_subclonal_25_percent",
          "MDS-related mutation(s): DNMT3A, TET2_subclonal_15_percent, TET2_clonal_45_percent => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => FLT3_ITD_subclonal_25_percent",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.890054",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD_subclonal_25_percent": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "subclonal",
          "blasts_percentage": 20
        }
      },
      {
        "test_id": "test_242_vaf_threshold_testing",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD_clonal_55_percent": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "clonal",
          "blasts_percentage": 20
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: FLT3_ITD_clonal_55_percent",
          "MDS-related mutation(s): DNMT3A, TET2_subclonal_15_percent, TET2_clonal_45_percent => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => FLT3_ITD_clonal_55_percent",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "vaf_threshold_testing",
        "timestamp": "2025-06-07T15:13:02.890092",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD_clonal_55_percent": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2_subclonal_15_percent": true,
            "TET2_clonal_45_percent": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "subclonal_vs_clonal_mutations",
          "scenario_description": "Subclonal vs clonal presentation of key mutations",
          "vaf_level": "unknown",
          "clonality": "clonal",
          "blasts_percentage": 20
        }
      },
      {
        "test_id": "test_243_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_low_ratio",
          "blasts_percentage": 75,
          "flt3_itd_allelic_ratio": 0.3,
          "age": 55
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890128",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_low_ratio",
          "blasts_percentage": 75,
          "flt3_itd_allelic_ratio": 0.3,
          "age": 55
        }
      },
      {
        "test_id": "test_244_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_high_ratio",
          "blasts_percentage": 68,
          "flt3_itd_allelic_ratio": 0.8,
          "age": 45
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 68",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 68",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890160",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_high_ratio",
          "blasts_percentage": 68,
          "flt3_itd_allelic_ratio": 0.8,
          "age": 45
        }
      },
      {
        "test_id": "test_245_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "cebpa_bzip_with_mds_mutations",
          "blasts_percentage": 55,
          "age": 62
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "MDS-related mutation(s): DNMT3A, TET2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890201",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "cebpa_bzip_with_mds_mutations",
          "blasts_percentage": 55,
          "age": 62
        }
      },
      {
        "test_id": "test_246_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true,
            "KIT": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "core_binding_factor_with_kit_mutation",
          "blasts_percentage": 45,
          "age": 35
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1_RUNX1T1, KIT",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1_RUNX1T1, KIT",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890241",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true,
            "KIT": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "core_binding_factor_with_kit_mutation",
          "blasts_percentage": 45,
          "age": 35
        }
      },
      {
        "test_id": "test_247_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "npm1_with_adverse_genetics",
          "blasts_percentage": 70,
          "age": 65
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 70",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 70",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890276",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "npm1_with_adverse_genetics",
          "blasts_percentage": 70,
          "age": 65
        }
      },
      {
        "test_id": "test_248_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "normal_karyotype_adverse_mutations",
          "blasts_percentage": 60,
          "age": 58
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, EZH2, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890312",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "normal_karyotype_adverse_mutations",
          "blasts_percentage": 60,
          "age": 58
        }
      },
      {
        "test_id": "test_249_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "complex_karyotype_with_npm1",
          "blasts_percentage": 45,
          "age": 67
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890344",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "complex_karyotype_with_npm1",
          "blasts_percentage": 45,
          "age": 67
        }
      },
      {
        "test_id": "test_250_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_very_low_vs_low_risk",
          "blasts_percentage": 3,
          "age": 72
        },
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 3, fibrotic: False",
          "SF3B1 mutation detected => MDS with low blasts and SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 3",
          "SF3B1 mutation detected => MDS with mutated SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with mutated SF3B1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_SF3B1",
        "icc_disease_type": "MDS_SF3B1",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts and SF3B1",
          "icc_classification": "MDS with mutated SF3B1",
          "who_category": "MDS_SF3B1",
          "icc_category": "MDS_SF3B1",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890386",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_very_low_vs_low_risk",
          "blasts_percentage": 3,
          "age": 72
        }
      },
      {
        "test_id": "test_251_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_low_vs_intermediate_risk",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2,
          "age": 65
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890425",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_low_vs_intermediate_risk",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2,
          "age": 65
        }
      },
      {
        "test_id": "test_252_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_intermediate_vs_high_risk",
          "blasts_percentage": 15,
          "age": 70
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890481",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_intermediate_vs_high_risk",
          "blasts_percentage": 15,
          "age": 70
        }
      },
      {
        "test_id": "test_253_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_high_vs_very_high_risk",
          "blasts_percentage": 18,
          "age": 68
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890525",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_high_vs_very_high_risk",
          "blasts_percentage": 18,
          "age": 68
        }
      },
      {
        "test_id": "test_254_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_aml_with_favorable_genetics",
          "blasts_percentage": 55,
          "age": 58
        },
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
          "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890569",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_aml_with_favorable_genetics",
          "blasts_percentage": 55,
          "age": 58
        }
      },
      {
        "test_id": "test_255_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_mds_with_tp53",
          "blasts_percentage": 12,
          "age": 62
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
          "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS, therapy related",
          "who_category": "MDS_TP53",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890624",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_mds_with_tp53",
          "blasts_percentage": 12,
          "age": 62
        }
      },
      {
        "test_id": "test_256_risk_stratification_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_after_immune_therapy",
          "blasts_percentage": 18,
          "age": 45
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "risk_stratification_boundaries",
        "timestamp": "2025-06-07T15:13:02.890682",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_after_immune_therapy",
          "blasts_percentage": 18,
          "age": 45
        }
      },
      {
        "test_id": "test_257_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890721",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        }
      },
      {
        "test_id": "test_258_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890757",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        }
      },
      {
        "test_id": "test_259_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890796",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        }
      },
      {
        "test_id": "test_260_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "MDS with excess blasts",
          "who_category": "AML_GENETIC",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 85,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'npm1'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Favorable vs Unknown",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890848",
        "significance": "critical",
        "clinical_impact_score": 85,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'npm1'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Favorable vs Unknown",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "mild"
        }
      },
      {
        "test_id": "test_261_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890901",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        }
      },
      {
        "test_id": "test_262_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.890953",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        }
      },
      {
        "test_id": "test_263_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891003",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        }
      },
      {
        "test_id": "test_264_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891036",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "moderate"
        }
      },
      {
        "test_id": "test_265_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891086",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        }
      },
      {
        "test_id": "test_266_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891136",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        }
      },
      {
        "test_id": "test_267_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891185",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        }
      },
      {
        "test_id": "test_268_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891219",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "single_lineage_dysplasia_gradations",
          "scenario_description": "Single lineage dysplasia with varying severity",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 1,
          "dysplasia_severity": "severe"
        }
      },
      {
        "test_id": "test_269_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891268",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        }
      },
      {
        "test_id": "test_270_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891316",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        }
      },
      {
        "test_id": "test_271_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891373",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        }
      },
      {
        "test_id": "test_272_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891423",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_megakaryocytic"
        }
      },
      {
        "test_id": "test_273_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891472",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        }
      },
      {
        "test_id": "test_274_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891522",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        }
      },
      {
        "test_id": "test_275_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891574",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        }
      },
      {
        "test_id": "test_276_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891622",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "erythroid_granulocytic"
        }
      },
      {
        "test_id": "test_277_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, TET2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891662",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        }
      },
      {
        "test_id": "test_278_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): U2AF1, DNMT3A => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891699",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        }
      },
      {
        "test_id": "test_279_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891738",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        }
      },
      {
        "test_id": "test_280_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891775",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 20,
          "number_of_dysplastic_lineages": 3,
          "primary_dysplasia": "trilineage"
        }
      },
      {
        "test_id": "test_281_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 14, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891826",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        }
      },
      {
        "test_id": "test_282_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 14, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891907",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        }
      },
      {
        "test_id": "test_283_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 14, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.891968",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        }
      },
      {
        "test_id": "test_284_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892023",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "multilineage_dysplasia_patterns",
          "scenario_description": "Different patterns of multilineage dysplasia",
          "blasts_percentage": 14,
          "number_of_dysplastic_lineages": 2,
          "primary_dysplasia": "granulocytic_megakaryocytic"
        }
      },
      {
        "test_id": "test_285_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892064",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_286_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892107",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_287_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892145",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_288_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "MDS with excess blasts",
          "who_category": "AML_GENETIC",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 85,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'npm1'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Favorable vs Unknown",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892197",
        "significance": "critical",
        "clinical_impact_score": 85,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'npm1'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Favorable vs Unknown",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 5,
          "ring_sideroblasts_percent": 20,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_289_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892237",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_290_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892273",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_291_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892309",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_292_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 but blasts <10 => cannot label AML here",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "MDS with excess blasts",
          "who_category": "AML_GENETIC",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 85,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'npm1'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [
            "Molecular vs flow cytometry MRD monitoring",
            "Different sensitivity and specificity"
          ],
          "prognostic_implications": [
            "Risk category: Favorable vs Unknown",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892357",
        "significance": "critical",
        "clinical_impact_score": 85,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'npm1'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [
          "Molecular vs flow cytometry MRD monitoring",
          "Different sensitivity and specificity"
        ],
        "prognostic_implications": [
          "Risk category: Favorable vs Unknown",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 8,
          "ring_sideroblasts_percent": 35,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_293_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892411",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_294_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892463",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_295_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892515",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_296_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892550",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 12,
          "ring_sideroblasts_percent": 25,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_297_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892600",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_298_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892650",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_299_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892700",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_300_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892735",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "dysplasia_with_ring_sideroblasts",
          "scenario_description": "Dysplastic changes with ring sideroblasts",
          "blasts_percentage": 18,
          "ring_sideroblasts_percent": 40,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_301_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892788",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_302_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892838",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_303_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892871",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_304_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.892954",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_305_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893004",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_306_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893053",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_307_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893085",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_308_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893135",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_309_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): DNMT3A, TET2, ASXL1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893175",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_310_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893216",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_311_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893249",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_312_nuanced_dysplasia_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): TP53 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "nuanced_dysplasia_patterns",
        "timestamp": "2025-06-07T15:13:02.893285",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "TP53": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "minimal_dysplasia_with_genetics",
          "scenario_description": "Minimal morphologic dysplasia but significant genetic abnormalities",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 0,
          "morphologic_dysplasia": "minimal"
        }
      },
      {
        "test_id": "test_313_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "chip_stage",
          "blasts_percentage": 2,
          "mutation_vaf": 15,
          "cytopenias": "mild"
        },
        "who_classification": "MDS, unclassifiable",
        "icc_classification": "MDS, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 2",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 2, fibrotic: False",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, unclassifiable (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 2",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 2",
          "number_of_dysplastic_lineages: None",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_NOS",
        "icc_disease_type": "MDS_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, unclassifiable",
          "icc_classification": "MDS, NOS",
          "who_category": "MDS_NOS",
          "icc_category": "MDS_NOS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893325",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "chip_stage",
          "blasts_percentage": 2,
          "mutation_vaf": 15,
          "cytopenias": "mild"
        }
      },
      {
        "test_id": "test_314_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "early_mds",
          "blasts_percentage": 5,
          "mutation_vaf": 25,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893362",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "early_mds",
          "blasts_percentage": 5,
          "mutation_vaf": 25,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_315_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "progressive_mds",
          "blasts_percentage": 12,
          "mutation_vaf": 35,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893413",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "chip_to_mds_evolution",
          "scenario_description": "CHIP progression to overt MDS",
          "evolution_stage": "progressive_mds",
          "blasts_percentage": 12,
          "mutation_vaf": 35,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_316_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "stable_mds",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893451",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "stable_mds",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_317_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "high_risk_mds",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893503",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "high_risk_mds",
          "blasts_percentage": 15,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_318_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_myeloid_malignancy": "Previous MDS"
          },
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "secondary_aml",
          "blasts_percentage": 28
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: FLT3_ITD",
          "MDS-related mutation(s): SF3B1, TET2, ASXL1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 28",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => FLT3_ITD",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893546",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_myeloid_malignancy": "Previous MDS"
          },
          "scenario_name": "mds_to_aml_transformation",
          "scenario_description": "MDS transformation to secondary AML",
          "evolution_stage": "secondary_aml",
          "blasts_percentage": 28
        }
      },
      {
        "test_id": "test_319_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_30_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "single_tp53_hit",
          "blasts_percentage": 10
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_30_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893596",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_30_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "single_tp53_hit",
          "blasts_percentage": 10
        }
      },
      {
        "test_id": "test_320_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "biallelic_tp53_loss",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893645",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "biallelic_tp53_loss",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_321_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "therapy_resistant_clone",
          "blasts_percentage": 35
        },
        "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML, myelodysplasia related, previous cytotoxic therapy",
          "Final classification => AML, myelodysplasia related, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 35",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related, previous cytotoxic therapy",
          "icc_classification": "AML with mutated TP53, therapy related",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 75,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type"
          ]
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893711",
        "significance": "high",
        "clinical_impact_score": 75,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "scenario_name": "tp53_driven_evolution",
          "scenario_description": "TP53-driven clonal evolution",
          "evolution_stage": "therapy_resistant_clone",
          "blasts_percentage": 35
        }
      },
      {
        "test_id": "test_322_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "early_splicing_defect",
          "blasts_percentage": 4,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with low blasts",
        "icc_classification": "MDS, NOS with single lineage dysplasia",
        "who_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 4, fibrotic: False",
          "Single dysplastic lineage => MDS with low blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 4",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 4",
          "number_of_dysplastic_lineages: 1",
          "Single lineage dysplasia => MDS, NOS with single lineage dysplasia",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, NOS with single lineage dysplasia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_DYSPLASIA",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts",
          "icc_classification": "MDS, NOS with single lineage dysplasia",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_DYSPLASIA",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893756",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "early_splicing_defect",
          "blasts_percentage": 4,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_323_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "multiple_splicing_hits",
          "blasts_percentage": 9,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 9, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 9",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 9",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893796",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "multiple_splicing_hits",
          "blasts_percentage": 9,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_324_clonal_evolution_patterns",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true,
            "ASXL1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "splicing_plus_epigenetic",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 3
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 16, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "clonal_evolution_patterns",
        "timestamp": "2025-06-07T15:13:02.893849",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true,
            "ASXL1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "splicing_factor_evolution",
          "scenario_description": "Splicing factor mutation-driven evolution",
          "evolution_stage": "splicing_plus_epigenetic",
          "blasts_percentage": 16,
          "number_of_dysplastic_lineages": 3
        }
      },
      {
        "test_id": "test_325_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.893888",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_326_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.893925",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_327_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.893960",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_328_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.893997",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_329_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894031",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_330_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894067",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_331_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894101",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_332_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894161",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_333_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894211",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_334_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894250",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_335_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894311",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_336_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894384",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_337_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894451",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_338_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894506",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_339_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894656",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_340_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894719",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_341_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894779",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_342_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894828",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_343_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894883",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_344_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894936",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_345_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.894990",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_346_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895043",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_347_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895088",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_348_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895139",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_349_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895188",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_350_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895229",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_351_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895270",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_352_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895322",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_353_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895363",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_354_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895398",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_355_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895435",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_356_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895471",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_357_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895520",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_358_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895556",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_359_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895591",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_360_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895630",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_361_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895668",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_362_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895705",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_363_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895744",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_364_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895781",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_365_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895816",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_366_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895851",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_367_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895885",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_368_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895921",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_369_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.895956",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_370_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896011",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_371_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896065",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_372_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896109",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_373_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896162",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_374_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896212",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_375_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896264",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_376_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896321",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_377_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896362",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_378_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896412",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_379_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896463",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_380_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896515",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_381_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896605",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_382_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896647",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_383_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896697",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_384_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896746",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_385_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896786",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_386_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896823",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_387_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896875",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_388_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896911",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_389_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896946",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_390_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.896981",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_391_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897016",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_392_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897064",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_393_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897098",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_394_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897131",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_395_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897168",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_396_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897203",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_397_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897237",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_398_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897272",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_399_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897308",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_400_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897345",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_401_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897391",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_402_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897446",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_403_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897487",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_404_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897526",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_405_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897584",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_406_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897643",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_407_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897689",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_408_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897745",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_409_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897797",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_410_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897851",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_411_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897905",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_412_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.897948",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_413_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898018",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_414_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898161",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_415_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898291",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_416_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898427",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_417_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898473",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_418_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898620",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_419_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898697",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_420_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898745",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_421_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898785",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_422_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898839",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_423_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898880",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_424_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898917",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_425_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898955",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_426_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.898992",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_427_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899043",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_428_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899080",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_429_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899114",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_430_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899156",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_431_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899193",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_432_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899229",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_433_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899266",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_434_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899302",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_435_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899339",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_436_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899375",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_437_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899408",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_438_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899443",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_439_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899477",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_440_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899533",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_441_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899652",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_442_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899702",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_443_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899756",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_444_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899808",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_445_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899862",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_446_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899915",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_447_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.899957",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_448_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900012",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_449_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900062",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_450_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900139",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_451_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900215",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_452_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900264",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_453_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900324",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_454_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900382",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_455_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900426",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_456_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900465",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_457_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900519",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_458_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900559",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_459_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900628",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_460_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900666",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_461_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900704",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_462_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900755",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_463_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900792",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_464_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900826",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_465_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900865",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_466_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900905",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_467_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900940",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_468_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.900978",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_469_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901013",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_470_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901048",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_471_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901083",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_472_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901118",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_473_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901156",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_474_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901193",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_475_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901243",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_476_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901293",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_477_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901336",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_478_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901390",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_479_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901443",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_480_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901490",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_481_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901538",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_482_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901579",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_483_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901629",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_484_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901679",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_485_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901725",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_486_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901771",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_487_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901812",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_488_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901861",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_489_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901910",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_490_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML, NOS",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.901964",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_491_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML, NOS",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902013",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_492_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902064",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_493_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902101",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_494_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902137",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_495_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML, NOS",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902183",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_496_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML, NOS",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_NOS",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902229",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_497_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902278",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_498_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902314",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_499_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902347",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "simple_abnormalities",
          "complexity_description": "Simple cytogenetic abnormalities",
          "complexity_score": 1,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_500_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902386",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_501_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902423",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_502_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902458",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_503_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902494",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_504_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902528",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_505_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902565",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_506_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902601",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_507_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902635",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_508_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902670",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_509_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902705",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_510_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902760",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_511_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902816",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_512_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902860",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_513_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902912",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_514_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.902962",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_515_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903016",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_516_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903068",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_517_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903109",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_518_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903159",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_519_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903210",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_520_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903262",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_521_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903313",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_522_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903354",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_523_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903405",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_524_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903454",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_525_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903493",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_526_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903531",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_527_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903581",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_528_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903617",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_529_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903651",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_530_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903687",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_531_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903722",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_532_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_5q, del_7q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903771",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_533_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903807",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_534_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903843",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true,
            "del_7q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_535_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903881",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_536_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903943",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_537_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.903978",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_538_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904015",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_539_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904050",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_540_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904084",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_541_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904118",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_542_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904155",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_543_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904190",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_544_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904224",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_545_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904277",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_546_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904331",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_547_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904371",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_548_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904424",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_549_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904478",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_550_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904529",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_551_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904581",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_552_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904620",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_553_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904669",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_554_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904718",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_555_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904768",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_556_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904818",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_557_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904857",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_558_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904901",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_559_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904946",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_560_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.904981",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_561_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905015",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_562_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905063",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_563_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905098",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_564_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905132",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_565_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905189",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_566_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905228",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_567_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): -7, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905277",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_568_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905313",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_569_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905346",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "-7": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_570_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905384",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_571_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905430",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_572_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905472",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_573_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905535",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_574_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905575",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_575_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905612",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_576_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905660",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_577_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905697",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_578_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905733",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_579_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905767",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_580_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905822",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_581_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905880",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_582_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905923",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_583_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.905978",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_584_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906031",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_585_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906085",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_586_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906140",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_587_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906183",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_588_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906236",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_589_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906286",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_590_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906338",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_591_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906390",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_592_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906430",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_593_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906482",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_594_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906533",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_595_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906574",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_596_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906612",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_597_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906666",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_598_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906704",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_599_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906738",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_600_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906777",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_601_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906814",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_602_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): del_17p, del_5q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906863",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_603_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906900",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_604_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906936",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "del_17p": true,
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_605_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.906975",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_606_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907010",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_607_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907044",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_608_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907080",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_609_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907116",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_610_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907154",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_611_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907190",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_612_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907223",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_613_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907259",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_614_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907323",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_615_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907378",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_616_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907431",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_617_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907472",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_618_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907526",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_619_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907576",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_620_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907629",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_621_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907683",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_622_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907723",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_623_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907774",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_624_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907826",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_625_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907877",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_626_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907928",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_627_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.907970",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_628_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908019",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_629_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908070",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_630_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908109",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_631_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908146",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_632_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908197",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_633_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908234",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_634_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908274",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_635_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908310",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_636_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908346",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_637_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): inv3_t33, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908394",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_638_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908429",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_639_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908462",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "inv3_t33": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "intermediate_complexity",
          "complexity_description": "Intermediate cytogenetic complexity",
          "complexity_score": 2,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_640_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908499",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_641_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908536",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_642_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908569",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_643_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908604",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_644_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908640",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_645_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908673",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_646_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908706",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_647_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908737",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_648_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908770",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_649_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908804",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_650_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908855",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_651_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908902",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_652_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908939",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_653_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.908986",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_654_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909034",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_655_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909083",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_656_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909135",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_657_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909175",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_658_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909224",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_659_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909272",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_660_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909323",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_661_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909374",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_662_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909418",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_663_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909473",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_664_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909597",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_665_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909647",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_666_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909686",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_667_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909738",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_668_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909776",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_669_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909810",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_670_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909847",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_671_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909884",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_672_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909933",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_673_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.909969",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_674_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910006",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_675_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910044",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_676_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910080",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_677_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910113",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_678_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910152",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_679_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910190",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_680_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910228",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_681_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910264",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_682_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910298",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_683_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910333",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_684_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910369",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_685_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910423",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_686_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910479",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_687_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910520",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_688_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910572",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_689_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910624",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_690_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910676",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_691_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910762",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_692_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910808",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_693_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910859",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_694_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910909",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_695_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.910960",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_696_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911015",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_697_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911056",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_698_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911106",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_699_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911156",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_700_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911196",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_701_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911237",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_702_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911288",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_703_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911325",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_704_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911359",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_705_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911396",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_706_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911434",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_707_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_17p, del_5q, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911483",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_708_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911518",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_709_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911552",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true,
            "del_5q": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_710_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911591",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_711_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911627",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_712_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911663",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_713_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911698",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_714_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911733",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_715_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911768",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_716_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911802",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_717_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911835",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_718_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911870",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_719_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911906",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_720_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.911961",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_721_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912015",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_722_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912057",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_723_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912108",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_724_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912160",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_725_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912212",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_726_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912263",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_727_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912304",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_728_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912354",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_729_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912404",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_730_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912455",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_731_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912507",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_732_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912548",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_733_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912599",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_734_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912649",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_735_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912688",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_736_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912725",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_737_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912775",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_738_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912812",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_739_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912846",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_740_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912884",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_741_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912920",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_742_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.912967",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_743_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913004",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_744_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913041",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "complex_karyotype",
          "complexity_description": "Complex karyotype (\u22653 abnormalities)",
          "complexity_score": 4,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_745_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913080",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_746_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913119",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_747_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913152",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_748_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913193",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_749_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913233",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_750_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913269",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_751_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913303",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_752_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913337",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_753_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913372",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_754_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913405",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_755_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913462",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_756_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913515",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_757_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913557",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_758_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913608",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_759_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913658",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_760_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913713",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_761_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913766",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_762_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913808",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_763_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913858",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_764_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913907",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_765_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.913958",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_766_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914010",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_767_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914050",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_768_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914131",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_769_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914181",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_770_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914221",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_771_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914258",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_772_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914307",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_773_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914344",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_774_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914378",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_775_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914415",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_776_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914452",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_777_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, del_5q, del_7q, -7, del_17p, del_20q => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914504",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_778_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914539",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_779_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914655",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_5q": true,
            "del_7q": true,
            "-7": true,
            "del_17p": true,
            "del_20q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_780_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914711",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_781_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914750",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_782_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914786",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_783_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914823",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_784_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914859",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 5,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_785_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914894",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_786_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914931",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_787_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with mutated TP53"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.914964",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_788_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915001",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_789_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915036",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 8,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_790_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915093",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_791_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915149",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_792_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915192",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_793_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915247",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_794_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915298",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 12,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_795_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915351",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_796_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915419",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_797_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915601",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_798_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915666",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_799_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915742",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 15,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_800_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915862",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_801_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "MDS_TP53",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.915946",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_802_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916015",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_803_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916075",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_804_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916131",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 18,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_805_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916186",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_806_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916229",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_807_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916286",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_808_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916365",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_809_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916404",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 22,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_810_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916445",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "no_mutations"
        }
      },
      {
        "test_id": "test_811_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916486",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_single"
        }
      },
      {
        "test_id": "test_812_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No MDS-related mutations found.",
          "MDS-related cytogenetic(s): Complex_karyotype, -7, inv3_t33, del_17p, del_5q, del_12p => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "UNCLASSIFIABLE",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with mutated TP53",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "UNCLASSIFIABLE",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 90,
          "clinical_consequences": [
            "Targeted therapy eligibility differs: {'tp53'}",
            "Subtype classification differences within same disease category",
            "Therapy-related classification differs",
            "Genetic marker terminology differs"
          ],
          "treatment_implications": [
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [
            "Flow cytometry MRD only for both classifications",
            "Different genetic marker identification may affect MRD strategy"
          ],
          "prognostic_implications": [
            "Risk category: Intermediate vs High",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Potentially different prognosis within disease type",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916536",
        "significance": "critical",
        "clinical_impact_score": 90,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}",
          "Subtype classification differences within same disease category",
          "Therapy-related classification differs",
          "Genetic marker terminology differs"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications",
          "Different genetic marker identification may affect MRD strategy"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Potentially different prognosis within disease type",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "tp53_biallelic"
        }
      },
      {
        "test_id": "test_813_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916575",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "mds_mutations"
        }
      },
      {
        "test_id": "test_814_cytogenetic_complexity_gradations",
        "input_data": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SRSF2, U2AF1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "cytogenetic_complexity_gradations",
        "timestamp": "2025-06-07T15:13:02.916610",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "blasts_percentage": 25,
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "U2AF1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "-7": true,
            "inv3_t33": true,
            "del_17p": true,
            "del_5q": true,
            "del_12p": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "complexity_level": "very_complex_karyotype",
          "complexity_description": "Very complex karyotype (\u22655 abnormalities)",
          "complexity_score": 6,
          "mutation_combination": "splicing_mutations"
        }
      },
      {
        "test_id": "test_815_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 8
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: True",
          "5-9% blasts => MDS with increased blasts 1",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS with excess blasts",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916652",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 8
        }
      },
      {
        "test_id": "test_816_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 12
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916706",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_817_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 15
        },
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: True",
          "10-19% blasts => MDS with increased blasts 2",
          "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
          "Current classification: MDS, fibrotic",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS, fibrotic (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS, fibrotic",
          "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916760",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_818_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 80,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916812",
        "significance": "critical",
        "clinical_impact_score": 80,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_819_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 25
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916848",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "fibrotic_marrow_scenarios",
          "scenario_description": "Bone marrow fibrosis with different genetic backgrounds",
          "fibrotic": true,
          "bone_marrow_cellularity": "Fibrotic",
          "blasts_percentage": 25
        }
      },
      {
        "test_id": "test_820_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 5
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 5, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 5",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 5",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916886",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 5
        }
      },
      {
        "test_id": "test_821_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 8
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916924",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "-7": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 8
        }
      },
      {
        "test_id": "test_822_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 12
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.916966",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_823_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2, associated with Fanconi anemia",
        "icc_classification": "MDS/AML, NOS, in the setting of Fanconi anemia",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers => Not AML, consider MDS classification, associated with Fanconi anemia",
          "Final classification => Not AML, consider MDS classification, associated with Fanconi anemia",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "Detected germline predisposition => associated with Fanconi anemia",
          "Classification with qualifiers: MDS with increased blasts 2, associated with Fanconi anemia",
          "Final classification => MDS with increased blasts 2, associated with Fanconi anemia (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Qualifier => in the setting of Fanconi anemia",
          "Qualifiers appended => MDS/AML, NOS, in the setting of Fanconi anemia (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2, associated with Fanconi anemia",
          "icc_classification": "MDS/AML, NOS, in the setting of Fanconi anemia",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Germline implications differ"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Family screening recommendations differ",
            "Drug toxicity considerations differ"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917038",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Germline implications differ"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Family screening recommendations differ",
          "Drug toxicity considerations differ"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "predisposing_germline_variant": "Fanconi anemia"
          },
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_824_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DDX41": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 10,
          "age": 70
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917092",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "DDX41": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypoplastic_marrow_scenarios",
          "scenario_description": "Hypoplastic bone marrow with genetic abnormalities",
          "hypoplasia": true,
          "bone_marrow_cellularity": "Hypoplastic",
          "blasts_percentage": 10,
          "age": 70
        }
      },
      {
        "test_id": "test_825_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 6,
          "ring_sideroblasts_percent": 30
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 6",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 6, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 6",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 6",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917130",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 6,
          "ring_sideroblasts_percent": 30
        }
      },
      {
        "test_id": "test_826_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917179",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 12,
          "number_of_dysplastic_lineages": 2
        }
      },
      {
        "test_id": "test_827_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_AML_HYBRID",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML, NOS",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_AML_HYBRID",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "moderate_clinical_impact",
          "significance": "medium",
          "clinical_impact_score": 45,
          "clinical_consequences": [
            "Fundamental disease classification disagreement"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917231",
        "significance": "medium",
        "clinical_impact_score": 45,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 18,
          "number_of_dysplastic_lineages": 1
        }
      },
      {
        "test_id": "test_828_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 3
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): U2AF1, DNMT3A => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917269",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "U2AF1": true,
            "DNMT3A": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "hypercellular_marrow_scenarios",
          "scenario_description": "Hypercellular marrow with dysplastic changes",
          "bone_marrow_cellularity": "Hypercellular",
          "blasts_percentage": 22,
          "number_of_dysplastic_lineages": 3
        }
      },
      {
        "test_id": "test_829_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 8,
          "focal_dysplasia": true
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917305",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 8,
          "focal_dysplasia": true
        }
      },
      {
        "test_id": "test_830_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 14,
          "patchy_cellularity": true
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 14, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 14",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917355",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 14,
          "patchy_cellularity": true
        }
      },
      {
        "test_id": "test_831_microenvironment_interactions",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 16,
          "focal_fibrosis": true
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_del_17p': True}",
          "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 16",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "microenvironment_interactions",
        "timestamp": "2025-06-07T15:13:02.917397",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_del_17p": true
          },
          "qualifiers": {},
          "scenario_name": "mixed_cellularity_scenarios",
          "scenario_description": "Mixed cellularity patterns with focal abnormalities",
          "bone_marrow_cellularity": "Mixed",
          "blasts_percentage": 16,
          "focal_fibrosis": true
        }
      },
      {
        "test_id": "test_832_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_high_sensitivity",
          "blasts_percentage": 65,
          "age": 35
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 65",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917430",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_high_sensitivity",
          "blasts_percentage": 65,
          "age": 35
        }
      },
      {
        "test_id": "test_833_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_plus_FLT3",
          "blasts_percentage": 45,
          "age": 55
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917462",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_plus_FLT3",
          "blasts_percentage": 45,
          "age": 55
        }
      },
      {
        "test_id": "test_834_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_plus_epigenetic",
          "blasts_percentage": 25,
          "age": 65
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 25",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD, DNMT3A",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917494",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true,
            "DNMT3A": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "npm1_mrd_monitoring",
          "scenario_description": "NPM1+ AML with different MRD monitoring implications",
          "mrd_target": "NPM1_plus_epigenetic",
          "blasts_percentage": 25,
          "age": 65
        }
      },
      {
        "test_id": "test_835_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 10,
          "age": 60
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917546",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 10,
          "age": 60
        }
      },
      {
        "test_id": "test_836_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "TET2": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 15,
          "age": 70
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: TET2",
          "No AML-defining abnormality fully matched, blasts <20 => consider MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => TET2",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917598",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "TET2": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 15,
          "age": 70
        }
      },
      {
        "test_id": "test_837_mrd_methodology_differences",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "DNMT3A": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 20,
          "age": 80
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: DNMT3A",
          "MDS-related mutation(s): SF3B1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 20",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => DNMT3A",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "mrd_methodology_differences",
        "timestamp": "2025-06-07T15:13:02.917638",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "DNMT3A": true
          },
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "mds_mrd_monitoring",
          "scenario_description": "MDS cases with different MRD monitoring implications",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 20,
          "age": 80
        }
      },
      {
        "test_id": "test_838_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_low_ratio",
          "blasts_percentage": 75,
          "flt3_itd_allelic_ratio": 0.3,
          "age": 55
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 75",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917669",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_low_ratio",
          "blasts_percentage": 75,
          "flt3_itd_allelic_ratio": 0.3,
          "age": 55
        }
      },
      {
        "test_id": "test_839_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_high_ratio",
          "blasts_percentage": 68,
          "flt3_itd_allelic_ratio": 0.8,
          "age": 45
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 68",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1, FLT3_ITD",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 68",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1, FLT3_ITD",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917700",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true,
            "FLT3_ITD": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "npm1_flt3_itd_high_ratio",
          "blasts_percentage": 68,
          "flt3_itd_allelic_ratio": 0.8,
          "age": 45
        }
      },
      {
        "test_id": "test_840_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "cebpa_bzip_with_mds_mutations",
          "blasts_percentage": 55,
          "age": 62
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: CEBPA_bZIP",
          "MDS-related mutation(s): DNMT3A, TET2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => CEBPA_bZIP",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917737",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "CEBPA_bZIP": true
          },
          "MDS_related_mutation": {
            "DNMT3A": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "cebpa_bzip_with_mds_mutations",
          "blasts_percentage": 55,
          "age": 62
        }
      },
      {
        "test_id": "test_841_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true,
            "KIT": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "core_binding_factor_with_kit_mutation",
          "blasts_percentage": 45,
          "age": 35
        },
        "who_classification": "Acute myeloid leukaemia, unknown differentiation",
        "icc_classification": "AML, NOS",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: RUNX1_RUNX1T1, KIT",
          "No MDS-related mutations found.",
          "No MDS-related cytogenetic flags found.",
          "No AML_differentiation provided.",
          "No valid AML_differentiation => unknown differentiation",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Acute myeloid leukaemia, unknown differentiation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => RUNX1_RUNX1T1, KIT",
          "No single ICC AML-def abnormality triggered classification.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML, NOS (ICC 2022)"
        ],
        "who_disease_type": "UNCLASSIFIABLE",
        "icc_disease_type": "AML_NOS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "Acute myeloid leukaemia, unknown differentiation",
          "icc_classification": "AML, NOS",
          "who_category": "UNCLASSIFIABLE",
          "icc_category": "AML_NOS",
          "are_equivalent": true,
          "category_match": false,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917779",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "RUNX1_RUNX1T1": true,
            "KIT": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "favorable_vs_intermediate_risk_aml",
          "risk_description": "Cases at boundary between favorable and intermediate risk AML",
          "case_name": "core_binding_factor_with_kit_mutation",
          "blasts_percentage": 45,
          "age": 35
        }
      },
      {
        "test_id": "test_842_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "npm1_with_adverse_genetics",
          "blasts_percentage": 70,
          "age": 65
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 70",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 70",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917811",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "npm1_with_adverse_genetics",
          "blasts_percentage": 70,
          "age": 65
        }
      },
      {
        "test_id": "test_843_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "normal_karyotype_adverse_mutations",
          "blasts_percentage": 60,
          "age": 58
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): ASXL1, EZH2, RUNX1 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 60",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917846",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "EZH2": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "normal_karyotype_adverse_mutations",
          "blasts_percentage": 60,
          "age": 58
        }
      },
      {
        "test_id": "test_844_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "complex_karyotype_with_npm1",
          "blasts_percentage": 45,
          "age": 67
        },
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML with NPM1 mutation (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 45",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with mutated NPM1 (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation",
          "icc_classification": "AML with mutated NPM1",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917877",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "intermediate_vs_adverse_risk_aml",
          "risk_description": "Cases at boundary between intermediate and adverse risk AML",
          "case_name": "complex_karyotype_with_npm1",
          "blasts_percentage": 45,
          "age": 67
        }
      },
      {
        "test_id": "test_845_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_very_low_vs_low_risk",
          "blasts_percentage": 3,
          "age": 72
        },
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 3, fibrotic: False",
          "SF3B1 mutation detected => MDS with low blasts and SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 3",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 3",
          "SF3B1 mutation detected => MDS with mutated SF3B1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with mutated SF3B1 (ICC 2022)"
        ],
        "who_disease_type": "MDS_SF3B1",
        "icc_disease_type": "MDS_SF3B1",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with low blasts and SF3B1",
          "icc_classification": "MDS with mutated SF3B1",
          "who_category": "MDS_SF3B1",
          "icc_category": "MDS_SF3B1",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.917916",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true
          },
          "MDS_related_cytogenetics": {
            "del_5q": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_very_low_vs_low_risk",
          "blasts_percentage": 3,
          "age": 72
        }
      },
      {
        "test_id": "test_846_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_low_vs_intermediate_risk",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2,
          "age": 65
        },
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 8, fibrotic: False",
          "5-9% blasts => MDS with increased blasts 1",
          "Current classification: MDS with increased blasts 1",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 1 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 8",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts <10 => final classification: Not AML, consider MDS classification",
          "No germline predisposition indicated (review at MDT)",
          "Final => Not AML, consider MDS classification",
          "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
          "Default classification set to: MDS, NOS",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "blasts_percentage: 8",
          "5-9% blasts => MDS with excess blasts",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with excess blasts (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "MDS_BLASTS",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 1",
          "icc_classification": "MDS with excess blasts",
          "who_category": "MDS_BLASTS",
          "icc_category": "MDS_BLASTS",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918397",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SRSF2": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_low_vs_intermediate_risk",
          "blasts_percentage": 8,
          "number_of_dysplastic_lineages": 2,
          "age": 65
        }
      },
      {
        "test_id": "test_847_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_intermediate_vs_high_risk",
          "blasts_percentage": 15,
          "age": 70
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918448",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "RUNX1": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_intermediate_vs_high_risk",
          "blasts_percentage": 15,
          "age": 70
        }
      },
      {
        "test_id": "test_848_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_high_vs_very_high_risk",
          "blasts_percentage": 18,
          "age": 68
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with mutated TP53",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'2_x_TP53_mutations': True}",
          "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "Biallelic TP53 => AML with mutated TP53",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with mutated TP53",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with mutated TP53 (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "MDS_TP53",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML with mutated TP53",
          "who_category": "MDS_TP53",
          "icc_category": "MDS_TP53",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918491",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true,
            "del_17p": true
          },
          "Biallelic_TP53_mutation": {
            "2_x_TP53_mutations": true
          },
          "qualifiers": {},
          "risk_category": "mds_risk_stratification_boundaries",
          "risk_description": "MDS cases at risk stratification boundaries",
          "case_name": "mds_high_vs_very_high_risk",
          "blasts_percentage": 18,
          "age": 68
        }
      },
      {
        "test_id": "test_849_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_aml_with_favorable_genetics",
          "blasts_percentage": 55,
          "age": 58
        },
        "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated NPM1, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "Detected AML-defining abnormality flags: NPM1",
          "NPM1 => AML with NPM1 mutation",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic therapy",
          "Final classification => AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 55",
          "Default classification set to: AML, NOS",
          "ICC AML-defining flags => NPM1",
          "NPM1 => AML with mutated NPM1",
          "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)"
        ],
        "who_disease_type": "AML_GENETIC",
        "icc_disease_type": "AML_GENETIC",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML with NPM1 mutation, previous cytotoxic therapy",
          "icc_classification": "AML with mutated NPM1, therapy related",
          "who_category": "AML_GENETIC",
          "icc_category": "AML_GENETIC",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918535",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {
            "NPM1": true
          },
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_aml_with_favorable_genetics",
          "blasts_percentage": 55,
          "age": 58
        }
      },
      {
        "test_id": "test_850_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_mds_with_tp53",
          "blasts_percentage": 12,
          "age": 62
        },
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML, NOS, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "Detected WHO therapy => previous cytotoxic therapy: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Classification with qualifiers => Not AML, consider MDS classification, previous cytotoxic therapy",
          "Final classification => Not AML, consider MDS classification, previous cytotoxic therapy",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
          "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "No MDS-related genes set to True.",
          "No MDS-related cytogenetics triggered classification.",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML, NOS",
          "Detected ICC therapy => therapy related: Ionising radiation",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML, NOS, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_TP53",
        "icc_disease_type": "AML_THERAPY_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with biallelic TP53 inactivation",
          "icc_classification": "MDS/AML, NOS, therapy related",
          "who_category": "MDS_TP53",
          "icc_category": "AML_THERAPY_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "major_clinical_impact",
          "significance": "critical",
          "clinical_impact_score": 95,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Targeted therapy eligibility differs: {'tp53'}",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "TP53-directed therapy considerations",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: High vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918592",
        "significance": "critical",
        "clinical_impact_score": 95,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {},
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {
            "1_x_TP53_mutation_50_percent_vaf": true
          },
          "qualifiers": {
            "previous_cytotoxic_therapy": "Ionising radiation"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_mds_with_tp53",
          "blasts_percentage": 12,
          "age": 62
        }
      },
      {
        "test_id": "test_851_prognostic_score_boundaries",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_after_immune_therapy",
          "blasts_percentage": 18,
          "age": 45
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "Detected ICC therapy => therapy related: Immune interventions",
          "No germline predisposition indicated (review at MDT)",
          "Qualifiers appended => MDS/AML with myelodysplasia related gene mutation, therapy related (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation, therapy related",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "prognostic_score_boundaries",
        "timestamp": "2025-06-07T15:13:02.918650",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "ASXL1": true,
            "TET2": true
          },
          "MDS_related_cytogenetics": {},
          "Biallelic_TP53_mutation": {},
          "qualifiers": {
            "previous_cytotoxic_therapy": "Immune interventions"
          },
          "risk_category": "therapy_related_risk_stratification",
          "risk_description": "Therapy-related cases with different risk implications",
          "case_name": "tr_after_immune_therapy",
          "blasts_percentage": 18,
          "age": 45
        }
      },
      {
        "test_id": "test_852_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 10
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 10, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 10",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918700",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 10
        }
      },
      {
        "test_id": "test_853_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 12
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 12, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 12",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918750",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 12
        }
      },
      {
        "test_id": "test_854_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918798",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "flow_cytometry_vs_cytogenetics",
          "scenario_description": "Comparison of flow cytometry and cytogenetics for MDS/AML classification",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_855_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 15
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 15, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 15",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918849",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_high_sensitivity",
          "blasts_percentage": 15
        }
      },
      {
        "test_id": "test_856_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 18
        },
        "who_classification": "MDS with increased blasts 2",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => Not AML, consider MDS classification",
          "AML classifier indicated that the case is not AML. Switching to MDS classification...",
          "Default classification set to: MDS, unclassifiable",
          "Checking for biallelic TP53: {}",
          "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
          "Retrieved blasts: 18, fibrotic: False",
          "10-19% blasts => MDS with increased blasts 2",
          "Current classification: MDS with increased blasts 2",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => MDS with increased blasts 2 (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 18",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
          "No germline predisposition indicated (review at MDT)",
          "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "MDS_BLASTS",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": false,
        "difference_analysis": {
          "who_classification": "MDS with increased blasts 2",
          "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
          "who_category": "MDS_BLASTS",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": false,
          "category_match": false,
          "difference_type": "significant_clinical_impact",
          "significance": "high",
          "clinical_impact_score": 60,
          "clinical_consequences": [
            "Fundamental disease classification disagreement",
            "Therapy-related classification differs"
          ],
          "treatment_implications": [
            "Intensive chemotherapy vs supportive care",
            "Stem cell transplant eligibility differs",
            "Clinical trial eligibility differs",
            "Different approach to therapy-related disease"
          ],
          "mrd_implications": [],
          "prognostic_implications": [
            "Risk category: Unknown vs Intermediate",
            "Different survival expectations",
            "Different treatment intensity recommendations",
            "Different prognosis for therapy-related vs de novo disease"
          ]
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918897",
        "significance": "high",
        "clinical_impact_score": 60,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Therapy-related classification differs"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "Different approach to therapy-related disease"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations",
          "Different prognosis for therapy-related vs de novo disease"
        ],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_plus_TET2",
          "blasts_percentage": 18
        }
      },
      {
        "test_id": "test_857_lab_methodology_dependent",
        "input_data": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 22
        },
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
          "All AML-defining recurrent genetic abnormality flags are false.",
          "MDS-related mutation(s): SF3B1, TET2, DNMT3A, SRSF2 => AML, myelodysplasia related",
          "No AML_differentiation provided.",
          "No germline predisposition indicated (review at MDT)",
          "Final classification => AML, myelodysplasia related (WHO 2022)"
        ],
        "icc_derivation": [
          "Retrieved blasts_percentage: 22",
          "Default classification set to: AML, NOS",
          "No ICC AML-defining abnormality is True.",
          "No biallelic TP53 conditions met.",
          "MDS-related genes => AML with myelodysplasia related gene mutation",
          "Blasts >=20 => remain AML",
          "No germline predisposition indicated (review at MDT)",
          "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
        ],
        "who_disease_type": "AML_MDS_RELATED",
        "icc_disease_type": "AML_MDS_RELATED",
        "are_equivalent": true,
        "difference_analysis": {
          "who_classification": "AML, myelodysplasia related",
          "icc_classification": "AML with myelodysplasia related gene mutation",
          "who_category": "AML_MDS_RELATED",
          "icc_category": "AML_MDS_RELATED",
          "are_equivalent": true,
          "category_match": true,
          "difference_type": "terminology_only",
          "significance": "minimal",
          "clinical_impact_score": 0,
          "clinical_consequences": [
            "Terminology difference only - same clinical entity"
          ],
          "treatment_implications": [],
          "mrd_implications": [],
          "prognostic_implications": []
        },
        "test_focus": "lab_methodology_dependent",
        "timestamp": "2025-06-07T15:13:02.918934",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [
          "Terminology difference only - same clinical entity"
        ],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": [],
        "test_case": {
          "AML_defining_recurrent_genetic_abnormalities": {},
          "MDS_related_mutation": {
            "SF3B1": true,
            "TET2": true,
            "DNMT3A": true,
            "SRSF2": true
          },
          "MDS_related_cytogenetics": {
            "Complex_karyotype": true
          },
          "Biallelic_TP53_mutation": {},
          "qualifiers": {},
          "scenario_name": "molecular_technologies_comparison",
          "scenario_description": "Comparison of molecular technologies for MRD detection",
          "mrd_target": "SF3B1_plus_epigenetic",
          "blasts_percentage": 22
        }
      }
    ],
    "timestamp": "2025-06-07T15:13:03.029442",
    "total_tests": 857
  }